

Producing Amines And Diamines From A Carboxylic Acid Or Dicarboxylic Acid Or A Monoester Thereof

5 The invention relates to a whole-cell catalyst which expresses a recombinant α -dioxxygenase and/or the combination of a recombinant fatty acid reductase and of a phosphopantetheinyl transferase which phosphopantetheinylates the fatty acid reductase, and which additionally expresses a transaminase, wherein the phosphopantetheinyl transferase and/or transaminase is preferably recombinant; and also to a process for converting a carboxylic acid or dicarboxylic
10 acid or a monoester thereof to an amine or diamine, comprising the steps of contacting the carboxylic acid or dicarboxylic acid or the monoester thereof with a phosphopantetheinylated fatty acid reductase or an α -dioxxygenase and contacting the product with a transaminase.

Polyamides are a class of polymers which are characterized by repeating amide groups. In
15 contrast to the chemically related proteins, the term "polyamide" usually relates to synthetic, commercially available, thermoplastic polymers. Polyamides are derived from primary amines or from secondary amines which are conventionally obtained via cracked hydrocarbons. However, it is also possible to use derivatives, more precisely aminocarboxylic acids, lactams and diamines, for producing the polymer. Also of interest as starting materials are short-chain,
20 gaseous alkanes which can be obtained proceeding from renewable raw materials using biotechnological processes.

The conventional chemical-technical production of such amines and diamines is dependent on the supply of fossil raw materials, inefficient, and in the process large amounts of undesired by-
25 products are produced, in some steps of the synthesis up to 80%. An example of such a process is the production of laurolactam. Conventionally, this is carried out via a multi-stage process which not only delivers a low yield, but also simultaneously requires the provision of a complex infrastructure.

30 In view of the said disadvantages, processes have been developed in order to obtain amines and diamines using biocatalysts starting from renewable raw materials. Suitable renewable raw materials are in particular sources of fatty acids which can be obtained in the form of rapeseed oil, globe thistle oil, palm kernel oil, coconut oil, sunflower kernel oil and similar natural products from a large number of biological sources, in particular from plants.

PCT/EP 2008/067447 describes a biotechnological system for producing chemically related products, more precisely ω -aminocarboxylic acids, using a cell which has a series of suitable enzymatic activities and is able to convert carboxylic acids to corresponding ω -aminocarboxylic acid. The process comprises a cascade of enzymatically catalysed reactions, more particularly
5 the oxidation of a fatty acid at the terminal carbon atom to the aldehyde and the subsequent amination using a transaminase and an amino acid as amine donor, which can be regenerated via an amino acid dehydrogenase.

A known disadvantage of the AlkBGT oxidase system from *Pseudomonas putida* GPO1 used
10 therein, however, is that it is not able to achieve selective oxidation of aliphatic alkanes to primary alcohols. Rather, a multitude of oxidation products arise; in particular, the fraction of more highly oxidized products, such as the corresponding aldehyde, ketone or the corresponding carboxylic acid, increases with increasing reaction time (C. Grant, J. M. Woodley and F. Baganz (2011), *Enzyme and Microbial Technology* 48, 480-486), which correspondingly
15 reduces the yield of desired amine.

The problem of the relatively unselective oxidation is exacerbated by the fact that the corresponding oxidation products are structurally very similar. This means that it is very difficult to separate them off from the desired oxidation products efficiently and without a significant loss
20 in yield.

A further disadvantage of this process is that overoxidized by-products, for example the dicarboxylic acid of the fatty acid used as reactant, the recycling of hydrophobic solvents and hydrophobic liquid cation exchangers which can be used as per PCT/EP2011/071491 for
25 removing the product from the aqueous reaction mixture, are damaging to efficiency in resource utilization.

In this connection, it should be emphasized that the complexity of biotechnological systems having a cascade of reactions such as the one described in PCT/EP 2008/067447, wherein
30 each reaction is catalysed by a particular enzyme, makes it difficult to optimize the reaction conditions. For instance, in the case of the fundamentally reactive ω -amino fatty acids as product, there is the possibility that, from a certain critical concentration inside the cell, they react with essential constituents of the organism and thus have a toxic effect. If this is the case, the growth and synthesis capacity of the organism is impaired through to cell death, without the

developer being able to immediately recognize the toxicity or to even assign it to a particular reactant, intermediate product or product. Which organism tolerates which concentration of a chemically reactive substance is likewise not predictable.

- 5 Also with regard to a product yield that is to be improved and a by-product development that is to be reduced, a person skilled in the art cannot routinely identify limiting and critical factors in a system such as the one described in PCT/EP2008/067447. If the yield of product is too low, this can be due to the fact that one of the enzymes is present in an excessively low concentration, without it being known which of the possible enzymes it is, i.e. the reactant is not converted
10 within the intended period or before degradation by competing enzymes owing to insufficient synthesis capacity. Alternatively, it is by all means possible that an enzyme is indeed detectable in the cell in the form of a polypeptide, but, specifically in this cell, does not have the folding essential to the activity or lacks a hitherto unknown cofactor that is, however, essential to the activity. Similarly, as already mentioned, the metabolic product may be toxic to the cell or be
15 degraded. Lastly, interfering interactions with endogenous enzymes, i.e. enzymes naturally present in a cell used as whole-cell catalyst, should be expected.

There is therefore a need for processes for producing alkyl monoamines and diamines from fatty acids, in which the enzymatically catalysed reactions proceed more selectively and the
20 formation of undesired by-products is minimized.

Against this background, it is an object of the invention to provide a biotechnological process for producing alkyl monoamines and diamines from fatty acids that is as efficient as possible with regard to yield, carbon and/or nitrogen balance and/or purity.

25

It is also an object of the invention to provide a biotechnological process for producing alkyl monoamines and diamines from fatty acids that is as efficient as possible with regard to yield, carbon and/or nitrogen balance, reusability of agents used and/or purity of the product. In this connection, an efficient carbon and/or nitrogen balance is preferably understood as meaning
30 that a very high proportion of the carbon and/or nitrogen fed to a cell for converting a carboxylic acid or a carboxylic ester in the form of suitable substrates is recovered in the desired final product, instead of, for example, being converted to products other than the one desired.

It is also an object of the invention to improve the ability of a multi-phase reaction mixture from the production of alkyl monoamines and diamines from fatty acids to be worked up, especially with regard to reusability relating to work-up of used hydrophobic solvent and liquid cation exchanger, and also with regard to phase formation and separation in a biphasic system comprising an aqueous phase in which the conversion of the carboxylic acid or the carboxylic ester proceeds, and an organic phase containing organic solvents and/or liquid cation exchangers.

These and further objects are achieved by the subject matter of the present application and in particular also by the subject matter of the accompanying independent claims, the dependent claims specifying embodiments of the invention.

In a first aspect, the object underlying the invention is achieved by a whole-cell catalyst which expresses a recombinant α -dioxygenase or the combination of a recombinant fatty acid reductase and of a phosphopantetheinyl transferase which phosphopantetheinylates the fatty acid reductase, and which additionally expresses a transaminase, wherein the phosphopantetheinyl transferase and/or transaminase is preferably recombinant.

In a first embodiment of the first aspect, the object is achieved by a whole-cell catalyst which additionally expresses an amino acid dehydrogenase which is preferably recombinant.

In a second embodiment, which is also an embodiment of the first embodiment, the object is achieved by a whole-cell catalyst which additionally expresses an alkane hydroxylase which is preferably recombinant.

In a third embodiment, which is also an embodiment of the first to second embodiment, the object is achieved by a whole-cell catalyst which additionally expresses a polypeptide of the AlkL family, which polypeptide is preferably recombinant.

In a fourth embodiment, which is also an embodiment of the second embodiment, the object is achieved by a whole-cell catalyst which additionally expresses an alcohol dehydrogenase which is preferably recombinant.

In a fifth embodiment, which is also an embodiment of the first to fourth embodiment, the object is achieved by a whole-cell catalyst, wherein the activity of at least one enzyme involved in the β -oxidation is reduced with respect to the wild type of the whole-cell catalyst.

5

In a sixth embodiment, which is also an embodiment of the first to fifth embodiment, the object is achieved by a whole-cell catalyst, wherein the activity of BioH or a variant thereof is reduced or elevated with respect to the wild type of the whole-cell catalyst.

10 In a seventh embodiment, which is also an embodiment of the first to sixth embodiment, the object is achieved by a whole-cell catalyst, wherein the activity of FadL or a variant thereof is elevated with respect to the wild type of the whole-cell catalyst.

15 In a second aspect, the object underlying the invention is achieved by a process for converting a carboxylic acid or dicarboxylic acid or a monoester thereof to an amine or diamine, comprising the steps of

a) providing a carboxylic acid or dicarboxylic acid or a monoester thereof, in the case of a dicarboxylic acid, preferably by contacting a carboxylic acid with an alkane hydroxylase and/or alcohol dehydrogenase,

20

b) contacting the carboxylic acid or dicarboxylic acid or the monoester thereof with a phosphopantetheinylated fatty acid reductase or an α -dioxxygenase to form an aldehyde product, and

25

c) contacting the product from step a) with a transaminase.

In a second aspect, the object underlying the invention is achieved by a process, wherein an amino acid dehydrogenase is present in step c).

30

In a first embodiment of the second aspect, the object is achieved by a process, wherein at least one enzyme from the group comprising phosphopantetheinylated fatty acid reductase, α -dioxxygenase, transaminase, amino acid dehydrogenase and alkane hydroxylase, preferably all

the enzymes used from said group, are provided in the form of a whole-cell catalyst the first aspect of the present invention.

In a second embodiment, which is also an embodiment of the first embodiment, the object is achieved by a process, wherein the carboxylic acid or dicarboxylic acid or the monoester thereof is a compound of the formula (I)



where R^1 is selected from the group comprising -H and $COOR^3$,

where R^2 and R^3 are each independently selected from the group comprising H, methyl, ethyl and propyl,

with the proviso that at least one of the radicals R^2 and R^3 is H,

where A is an unbranched, branched, linear, cyclic, substituted or unsubstituted hydrocarbon group having at least four carbon atoms.

In a third embodiment, which is also an embodiment of the first to second embodiment, the object is achieved by a process, wherein A has the formula $-(CH_2)_n-$, where n is at least 4, preferably at least 10.

In a third aspect, the object underlying the invention is achieved by using the whole-cell catalyst according to the first aspect or the process according to the second aspect for aminating a fatty acid, ω -hydroxy fatty acid, ω -oxo fatty acid or a monoester thereof.

In a fourth aspect, the object underlying the invention is achieved by a reaction mixture comprising the whole-cell catalyst according to the first aspect in aqueous solution and also a fatty acid, ω -hydroxy fatty acid, ω -oxo fatty acid or a monoester thereof of the formula (I)



where R^1 is selected from the group comprising -H, -CHO, -OH and $COOR^3$,

where R^2 and R^3 are each independently selected from the group comprising H, methyl, ethyl and propyl,

5 with the proviso that at least one of the radicals R^2 and R^3 is H,

where A is an unbranched, branched, linear, cyclic, substituted or unsubstituted hydrocarbon group having at least four carbon atoms, preferably the formula - $(CH_2)_n$ -, where n is at least 4, particularly preferably at least 10.

10

The present invention is based on the finding by the inventor that a functionally recombinant fatty acid reductase or α -dioxygenase in a whole-cell catalyst which is used to produce amines and diamines from fatty acids and has a corresponding enzyme environment surprisingly
15 increases the yield of amines and diamines.

Furthermore, the present invention is based on the finding by the inventor that a functionally recombinant fatty acid reductase or α -dioxygenase in a whole-cell catalyst which is used to produce amines and diamines from fatty acids and has a corresponding enzyme environment
20 surprisingly reduces the concentration of interfering by-products, more particularly overoxidized fatty acids in the form of dicarboxylic acids and esters thereof, in the product which arises.

Furthermore, the present invention is based on the finding by the inventor that a functionally recombinant fatty acid reductase or α -dioxygenase in a whole-cell catalyst which is used to
25 produce amines and diamines fatty acids and has a corresponding enzyme environment improves the purity and reusability of liquid cation exchangers such as oleic acid, which are used to remove the amine and diamine from a fermentation solution comprising the whole-cell catalyst.

30

The present invention provides an improved process for converting a carboxylic acid or dicarboxylic acid or a monoester thereof to an amine or diamine, which process is notable for the fact that, besides the enzymes catalysing the transfer of the fatty acid via its various oxidation stages to the amine, a fatty acid reductase or α -dioxygenase is also present,

preferably when a whole-cell catalyst is used to carry out the process. In a preferred embodiment, the term "fatty acid reductase", as used herein, is understood to mean an enzyme which catalyses the conversion of a ω -carboxylic acid, also referred to as dicarboxylic acid or ω -carboxy fatty acid, to the corresponding ω -oxo fatty acid with consumption of ATP and

5 NAD(P)H. In the prior art, for example in WO/2010/135624, fatty acid reductases for producing ω -hydroxy fatty acids are described, but not as part of a system for producing ω -amino fatty acids. In an even more preferred embodiment, the fatty acid reductase is selected from the group of fatty acid reductases comprising the amino acid sequences YP_887275.1, ZP_11001941.1, ZP_06852401.1, NP_959974.1, YP_001070587.1, ZP_05217435.1,

10 YP_882653.1, YP_639435.1, ZP_10800193.1, YP_006452763.1, YP_006730440.1, ZP_11196216.1, YP_005349252.1, ZP_05224908.1, YP_005338837.1, YP_006307000.1, YP_005343991.1, ZP_11001942.1, ZP_09979565.1, YP_005003162.1, YP_953393.1, YP_001850422.1, ZP_11011489.1, ZP_12689264.1, YP_905678.1, ZP_09976919.1, YP_004746059.1, NP_217106.1, YP_004525443.1, NP_337166.1, ZP_09685823.1,

15 YP_978699.1, ZP_06437984.1, ZP_06514086.1, NP_856267.1, CAA19077.1, NP_301424.1, ZP_06522140.1, ZP_06518098.1, ZP_11008938.1, ZP_07432374.2, AAR91681.1, YP_006808747.1, YP_001851230.1, ZP_15327751.1, ZP_15455857.1, ZP_12874284.1, ZP_15332534.1, ZP_15512956.1, ZP_14244106.1, ZP_15470899.1, ZP_11439367.1, YP_001703694.1, ZP_15446742.1, YP_006808978.1, ZP_07964926.1, YP_006521379.1,

20 ZP_10796908.1, ZP_15512957.1, ZP_12874283.1, YP_005350955.1, ZP_14243341.1, YP_001705436.1, ZP_15329649.1, YP_006522325.1, YP_006732197.1, YP_003658971.1, ZP_05227804.1, YP_001703695.1, YP_006308707.1, ZP_15342047.1, YP_006521380.1, ZP_15327752.1, YP_005340557.1, ZP_11439578.1, ZP_15392943.1, ZP_15514789.1, ZP_12996178.1, ZP_09412214.1, ZP_06849686.1, YP_889972.1, YP_006570321.1,

25 ZP_15375693.1, YP_006308219.1, YP_006521600.1, YP_005340029.1, YP_005350457.1, ZP_11439836.1, ZP_12994664.1, ZP_14240588.1, ZP_14236860.1, ZP_09410830.1, YP_006731697.1, YP_005264225.1, YP_001704097.1, ZP_15328186.1, ZP_09402885.1, ZP_12690463.1, AFO59871.1, ZP_07966879.1, YP_118225.1, YP_001828302.1, YP_006566873.1, YP_003660169.1, ZP_15337407.1, ZP_08240521.1, ZP_10456477.1,

30 YP_001537947.1, YP_004016539.1, ZP_07664024.1, ZP_14244107.1, ZP_09794557.1, ZP_09274211.1, ZP_05224899.1, ZP_15484175.1, AAA17105.1, ZP_11437924.1, ZP_15446621.1, YP_003646340.1, ZP_15382134.1, ZP_14237669.1, ZP_09165547.1, YP_004019203.1, ZP_14240225.1, YP_001220863.1, CBA74242.1, ZP_12994240.1, EIE27140.1, ZP_15354547.1, ZP_15432557.1, ZP_15500132.1, ZP_15478632.1,

ZP_06846978.1, AAA17108.1, ZP_15333767.1, ZP_05217205.1, AAD44234.1,
 YP_005348984.1, YP_006306749.1, ZP_05224611.1, YP_005343772.1, YP_006730188.1,
 YP_882425.1, ZP_10799956.1, ZP_05045132.1, NP_960176.1, ZP_12398880.1,
 ZP_11192735.1, ZP_11440091.1, ZP_05217203.1, ZP_06846979.1, ZP_10800936.1,
 5 ZP_06523596.1, YP_882421.1, YP_006306748.1, YP_006522017.1, ZP_15432556.1,
 ZP_15354095.1, ZP_05227781.1, ZP_09684639.1, YP_006730187.1, YP_005343770.1,
 YP_005338616.1, YP_005348983.1, ZP_15472813.1, ZP_15457007.1, ZP_15421152.1,
 ZP_15488933.1, ZP_14240030.1, YP_001704825.1, ZP_15328982.1, YP_005911512.1,
 ZP_09411638.1, ZP_12876400.1, ZP_12995435.1, ZP_07667680.1, YP_001281387.1,
 10 EIE21044.1, ZP_15375054.1, NP_334518.1, 4DQV_A, ZP_06435375.1, YP_003030020.1,
 YP_976237.1, ZP_04926822.1, YP_004998149.1, YP_004743589.1, YP_005907921.1,
 NP_214615.1, YP_001286047.1, ZP_06515541.1, ZP_05139482.1, YP_888016.1,
 ZP_06452908.1, ZP_06519578.1, YP_004721827.1, CAJ77696.1, ZP_09680854.1,
 ZP_09686453.1, YP_884815.1, YP_884815.1,
 15 CAB55600.1, ZP_09081423.1, YP_006521568.1, ZP_11440626.1, ZP_15513309.1,
 ZP_09410778.1, ZP_15374248.1, ZP_15405954.1, YP_001704047.1, ZP_14236911.1,
 ZP_12873916.1, ZP_14242094.1, ZP_12994610.1, ZP_07664023.1, ZP_15446620.1,
 ZP_15484174.1, ZP_14240245.1, YP_005358845.1 and XP_002669159.1,
 more particularly YP_006731697.1, ZP_09839660.1, YP_001704097.1, YP_889972.1,
 20 ZP_05045132.1, ZP_09794557.1, ZP_08240521.1, NP_959974.1, ZP_10456477.1,
 YP_118225.1, NP_217106, YP_905678.1, YP_887275.1, ZP_11001941.1, YP_953393.1 and
 YP_005349252.1 variants thereof.

Fatty acid reductases are a group of enzymes which require for their activity a
 25 phosphopantetheinylation, i.e. the covalent attachment of a phosphopantetheinyl cofactor to the
 enzyme. Accordingly, the fatty acid reductase used according to the invention is
 phosphopantetheinylated, and a whole-cell catalyst expressing the fatty acid reductase
 expresses, either as part of its environment of endogenously expressed enzymes or in
 recombinant form, a phosphopantetheinyl transferase which phosphopantetheinylates the fatty
 30 acid reductase. In a preferred embodiment, the term "phosphopantetheinyl transferase", as
 used herein, is understood to mean an enzyme which transfers a phosphopantetheinyl moiety
 from a phosphopantetheinyl-CoA to an enzyme, preferably to the fatty acid reductase. In a
 particularly preferred embodiment, the phosphopantetheinyl transferase is selected from the
 group of phosphopantetheinyl transferases comprising the amino acid sequences ABI83656.1,

YP_006811024.1, YP_120266.1, YP_005265173.1, YP_004006671.1, ZP_08152482.1,
 ZP_11104141.1, ZP_14482198.1, YP_706581.1, ZP_10002626.1, ZP_09308410.1,
 YP_002783881.1, ZP_18276502.1, ZP_09271851.1, ZP_08204640.1, YP_002766085.1,
 ZP_09788717.1, ZP_09799863.1, ZP_10961877.1, YP_003273299.1, GAB86168.1,
 5 YP_006668875.1, ZP_08766535.1, ZP_09793386.1, ZP_09212827.1, ZP_09276344.1,
 ZP_09213870.1, ZP_09081490.1, ZP_10947586.1, YP_003658841.1, ZP_06852853.1,
 YP_953148.1, ZP_11011170.1, YP_639258.1, YP_886985.1, ZP_11194383.1,
 ZP_09681094.1, ZP_06455719.1, NP_337369.1, YP_004077819.1, NP_217310.1,
 YP_006452521.1, YP_005339056.1, ZP_05226335.1, ZP_07965127.1, ZP_07419314.2,
 10 NP_302077.1, YP_005003342.1, YP_005349465.1, ZP_10800435.1, ZP_06564430.1,
 YP_882860.1, YP_001135287.1, YP_001850220.1, ZP_05217634.1, YP_003646683.1,
 YP_004746246.1, ZP_15327906.1, ZP_09979035.1, YP_001703848.1, YP_906028.1,
 ZP_15395499.1, ZP_11438833.1, ZP_11005955.1, ZP_09410582.1, NP_961833.1,
 YP_001106197.1, ZP_14237113.1, YP_004085491.1, YP_003835595.1, ZP_12994399.1,
 15 YP_004523804.1, ZP_12690887.1, YP_003339468.1, ZP_06589331.1, YP_004801334.1,
 ZP_09974565.1, ZP_04608379.1, ZP_13037142.1, YP_712537.1, ZP_11236665.1,
 NP_630748.1, ZP_06527138.1, YP_003835167.1, CCH33620.1, ZP_10309401.1,
 ZP_08881396.1, YP_003102953.1, YP_003487252.1, ZP_08881565.1, YP_006263961.1,
 NP_822924.1, YP_004914569.1, ZP_09400366.1, AFV71333.1, ZP_07309518.1,
 20 ZP_09172171.1, ZP_06710898.1, CAN89630.1, ZP_06921116.1, ZP_08804003.1,
 ZP_19189663.1, ZP_10545589.1, YP_006248725.1, ZP_10455557.1, YP_004015869.1,
 ZP_08801530.1, ZP_10550999.1, YP_004492879.1, ZP_09958730.1, ZP_08286666.1,
 ZP_11212856.1, AAL15597.1, AAZ94407.1, ZP_19188802.1, AFF18625.1, ZP_06575404.1,
 AAK06801.1, ADC79635.1, YP_004080528.1, YP_004921314.1, ACY01405.1,
 25 YP_004584022.1, YP_003114157.1, YP_003203177.1, AFB69911.1, YP_006876460.1,
 ZP_08024798.1, YP_006269867.1, YP_006881814.1, CCK26150.1, ZP_07307765.1,
 ZP_07315112.1, YP_005466392.1, NP_824081.1, YP_003493882.1, ZP_06412387.1,
 ZP_10068239.1, ZP_08234258.1, YP_001822177.1, ZP_03979107.1, ZP_07979043.1,
 BAA22407.1, ZP_09402950.1, YP_003112617.1, NP_738483.1, YP_480609.1, EKX90208.1,
 30 BAE93744.1, BAB69186.1, ZP_04713061.1, YP_006881735.1, ZP_07274901.1,
 ZP_11379052.1, ZP_06581115.1, YP_006437406.1, ZP_12871839.1, NP_601186.1,
 ZP_08451808.1, YP_005057339.1, YP_005303909.1, ZP_07090824.1, YP_003783676.1,
 YP_004630011.1, ZP_06588772.1, AAX98203.1, AFK80329.1, ZP_08124665.1,
 ZP_03710365.1, AAB17877.1, ZP_07403633.1, ZP_11268660.1, ZP_07288841.1,

- ABV83217.1, ZP_16178576.1, AAG43513.1, ZP_09155938.1, YP_004605750.1,
 ZP_03918977.1, AAF71762.1, ZP_05007864.1, ZP_06836265.1, ZP_03934882.1,
 YP_001508477.1, ZP_06043756.1, ZP_05366306.1, YP_002835056.1, ZP_03933464.1,
 ZP_07469321.1, ZP_07713507.1, YP_005160553.1, NP_939820.1, AAU93794.1,
 5 ZP_14659796.1, ZP_14383679.1, YP_005058606.1, YP_001221073.1, ZP_08231568.1,
 YP_250920.1, ZP_11383249.1, YP_003916320.1, ZP_08681170.1, YP_001800249.1,
 YP_001157632.1, YP_166099.1, ZP_10088015.1, YP_004760065.1, ZP_07947675.1,
 YP_001603066.1, YP_003812683.1, YP_004403402.1, ZP_08292153.1, ZP_09471260.1,
 YP_004018108.1, ZP_05115352.1, AAD13565.1, ZP_09295321.1, YP_001535629.1,
 10 ZP_04607273.1, YP_006561753.1, ZP_00960958.1, YP_006571985.1, ZP_08862188.1,
 YP_002906426.1, CCK30433.1, ZP_13042493.1, ZP_09090153.1, YP_614397.1,
 ZP_11163860.1, YP_003983492.1, YP_004080668.1, ZP_09420475.1, ZP_05914565.1,
 ZP_01101149.1, ZP_14743088.1, YP_001239694.1, ZP_09127532.1, YP_003833873.1,
 ZP_08516197.1, ZP_10160483.1, ZP_01987188.1, ZP_01755304.1, ZP_08825027.1,
 15 ZP_05077116.1, YP_001444606.1, ZP_03392800.1, ZP_01057781.1, AFB69889.1,
 ZP_08815097.1 and AAO17175.1 and variants thereof. In a particularly preferred embodiment,
 the phosphopantetheinyl transferase is the one having the database code ABI83656.1 or a
 variant thereof.
- 20 As an alternative or in addition to the combination of fatty acid reductase and
 phosphopantetheinyl transferase, the whole-cell catalyst can also comprise an α -dioxxygenase.
 In a preferred embodiment, the term " α -dioxxygenase", as used herein, is understood to mean
 an enzyme which catalyses the conversion of a carboxylic acid and/or dicarboxylic acid or a
 monoester thereof with consumption of a molecule of oxygen and with elimination of a carbon
 25 dioxide molecule to a carboxylic acid and/or dicarboxylic acid or a monoester thereof which
 bears an aldehyde group at the terminal ω -carbon atom and is shortened by one carbon atom at
 the terminal ω -carbon atom with respect to the carboxylic acid and/or dicarboxylic acid or a
 monoester thereof used as reactant. In a particularly preferred embodiment, the α -dioxxygenase
 is selected from the group of α -dioxxygenases comprising the amino acid sequences
 30 NP_001066718.1, EAY82977.1, BAH79993.1, ABG22011.1, BAJ90503.1, AFD04418.1,
 AFD04417.1, BAJ87736.1, AFW75180.1, ABG22012.1, XP_002311389.1, CAH05011.1,
 XP_002279884.1, CBI34957.3, AAG59584.1, NP_001234414.1, NP_001234410.1,
 XP_003553942.1, XP_002275161.1, XP_003553937.1, CBI34960.3, CAA07589.1,

XP_003543402.1, XP_002517402.1, XP_002882184.1, NP_186791.1, AAK85133.1, CAN77070.1, XP_002529555.1, CAH64542.1, NP_001234061.1, XP_002281357.1, ADM21465.1, XP_002318527.1, NP_177509.1, CAN74266.1, XP_002888940.1, NP_001185393.1, XP_003631072.1, BAJ33800.1, XP_002517377.1, XP_003530944.1, 5 BAJ34623.1, ABG22013.1, ABP02610.1, XP_001773135.1, XP_002960339.1, ABK95279.1, ABD73303.1, ABD73304.1, YP_001805721.1, ZP_08971815.1, ZP_08430366.1, YP_823013.1, ZP_05026427.1, ZP_11003953.1, YP_007064484.1, YP_007113008.1, YP_633369.1, ZP_18906570.1, ZP_09251410.1, ZP_10050808.1, ZP_01306662.1, YP_001516886.1, ZP_05042862.1, AAC49625.1, ZP_09648375.1, ZP_09792714.1, ZP_09788527.1, 10 XP_001728273.1, AAC83355.1, YP_890542.1, ZP_11000891.1, XP_002605323.1, EGO58341.1, YP_006249145.1, YP_001507004.1, YP_001704637.1, ZP_12876141.1, ZP_11150830.1, ZP_14236257.1, ZP_09411385.1, ZP_14243118.1, EKD16664.1, ZP_15416799.1, ZP_15338016.1, ZP_10080295.1, ZP_11438929.1, ZP_12995210.1, ZP_10946648.1, YP_003409541.1, XP_001637870.1, YP_005451221.1, XP_001212758.1, 15 ZP_07290489.1, ZP_05781329.1, ZP_19187748.1, ZP_06574534.1, XP_002605322.1, NP_822950.1, YP_006366425.1, EJP63377.1, EKD21217.1, XP_001795927.1, XP_003042615.1, ZP_06566152.1, EGU88116.1, EFY94417.1, XP_388327.1, EKJ68934.1, ZP_07290463.1, CCC10458.1, YP_001107201.1, XP_003348248.1, T49753, CAD31840.1, XP_001229975.1, CBN77040.1, YP_004813753.1, XP_002513273.1, XP_001627136.1, 20 AFG52858.1, AFG52857.1, AEW08450.1, NP_841291.1, YP_004512343.1, ACG75701.1 and ZP_03500906.1 and variants thereof. In a particularly preferred embodiment, the α -dioxygenase is the one having the database code NP_001066718.1 or a variant thereof.

Besides the α -dioxygenase or the combination of fatty acid reductase and the 25 phosphopantetheinyl transferase, the whole-cell catalyst according to the invention needs to have a transaminase which aminates terminal aldehyde groups. In a preferred embodiment, the term "transaminase", as used herein, is understood to mean an enzyme which catalyses the transfer of α -amino groups from a donor molecule, preferably an amino acid, to an acceptor molecule, preferably an α -ketocarboxylic acid. In a particularly preferred embodiment, the 30 transaminase is selected from the group of transaminases comprising the amino acid sequences 3HMU_A, AAD41041.1, AAK15486.1, ABE03917.1, ADR60699.1, ADR61066.1, ADR62525.1, AEL07495.1, CAZ86955.1, EFW82310.1, EFW87681.1, EGC99983.1, EGD03176.1, EGE58369.1, EGH06681.1, EGH08331.1, EGH24301.1,

EGH32343.1, EGH46412.1, EGH55033.1, EGH62152.1, EGH67339.1, EGH70821.1,
 EGH71404.1, EGH78772.1, EGH85312.1, EGH97105.1, EGP57596.1, NP_102850.1,
 NP_106560.1, NP_248912.1, NP_248990.1, NP_354026.2, NP_421926.1,
 NP_637699.1, NP_642792.1, NP_744329.1, NP_744732.1, NP_747283.1,
 5 NP_795039.1, NP_901695.1, XP_002943905.1, YP_001021095.1, YP_001059677.1,
 YP_001061726.1, YP_001066961.1, YP_001074671.1, YP_001120907.1,
 YP_001140117.1, YP_001170616.1, YP_001185848.1, YP_001188121.1,
 YP_001233688.1, YP_001268866.1, YP_001270391.1, YP_001345703.1,
 YP_001412573.1, YP_001417624.1, YP_001526058.1, YP_001579295.1,
 10 YP_001581170.1, YP_001668026.1, YP_001669478.1, YP_001671460.1,
 YP_001685569.1, YP_001747156.1, YP_001749732.1, YP_001765463.1,
 YP_001766294.1, YP_001790770.1, YP_001808775.1, YP_001809596.1,
 YP_001859758.1, YP_001888405.1, YP_001903233.1, YP_001977571.1,
 YP_002229759.1, YP_002231363.1, YP_002280472.1, YP_002297678.1,
 15 YP_002543874.1, YP_002549011.1, YP_002796201.1, YP_002801960.1,
 YP_002875335.1, YP_002897523.1, YP_002912290.1, YP_002974935.1,
 YP_003060891.1, YP_003264235.1, YP_003552364.1, YP_003578319.1,
 YP_003591946.1, YP_003607814.1, YP_003641922.1, YP_003674025.1,
 YP_003692877.1, YP_003755112.1, YP_003896973.1, YP_003907026.1,
 20 YP_003912421.1, YP_004086766.1, YP_004142571.1, YP_004147141.1,
 YP_004228105.1, YP_004278247.1, YP_004305252.1, YP_004356916.1,
 YP_004361407.1, YP_004378186.1, YP_004379856.1, YP_004390782.1,
 YP_004472442.1, YP_004590892.1, YP_004612414.1, YP_004676537.1,
 YP_004693233.1, YP_004701580.1, YP_004701637.1, YP_004704442.1,
 25 YP_108931.1, YP_110490.1, YP_168667.1, YP_237931.1, YP_260624.1,
 YP_262985.1, YP_271307.1, YP_276987.1, YP_334171.1, YP_337172.1,
 YP_350660.1, YP_351134.1, YP_364386.1, YP_366340.1, YP_369710.1,
 YP_370582.1, YP_426342.1, YP_440141.1, YP_442361.1, YP_468848.1,
 YP_521636.1, YP_554363.1, YP_608454.1, YP_610700.1, YP_614980.1,
 30 YP_622254.1, YP_625753.1, YP_680590.1, YP_751687.1, YP_767071.1,
 YP_774090.1, YP_774932.1, YP_788372.1, YP_858562.1, YP_928515.1,

YP_983084.1, YP_995622.1, ZP_00948889.1, ZP_00954344.1, ZP_00959736.1,
 ZP_00998881.1, ZP_01011725.1, ZP_01037109.1, ZP_01058030.1, ZP_01076707.1,
 ZP_01103959.1, ZP_01167926.1, ZP_01224713.1, ZP_01442907.1, ZP_01446892.1,
 ZP_01550953.1, ZP_01625518.1, ZP_01745731.1, ZP_01750280.1, ZP_01754305.1,
 5 ZP_01763880.1, ZP_01769626.1, ZP_01865961.1, ZP_01881393.1, ZP_01901558.1,
 ZP_02145337.1, ZP_02151268.1, ZP_02152332.1, ZP_02167267.1, ZP_02190082.1,
 ZP_02242934.1, ZP_02360937.1, ZP_02367056.1, ZP_02385477.1, ZP_02456487.1,
 ZP_02883670.1, ZP_03263915.1, ZP_03263990.1, ZP_03400081.1, ZP_03452573.1,
 ZP_03456092.1, ZP_03517291.1, ZP_03529055.1, ZP_03571515.1, ZP_03572809.1,
 10 ZP_03587785.1, ZP_03588560.1, ZP_03697266.1, ZP_03697962.1, ZP_04521092.1,
 ZP_04590693.1, ZP_04890914.1, ZP_04891982.1, ZP_04893793.1, ZP_04902131.1,
 ZP_04905327.1, ZP_04941068.1, ZP_04944536.1, ZP_04945255.1, ZP_04959332.1,
 ZP_04964181.1, ZP_05053721.1, ZP_05063588.1, ZP_05073059.1, ZP_05077806.1,
 ZP_05082750.1, ZP_05091128.1, ZP_05095488.1, ZP_05101701.1, ZP_05116783.1,
 15 ZP_05121836.1, ZP_05127756.1, ZP_05637806.1, ZP_05742087.1, ZP_05783548.1,
 ZP_05786246.1, ZP_05843149.1, ZP_05945960.1, ZP_06459045.1, ZP_06487195.1,
 ZP_06492453.1, ZP_06493162.1, ZP_06703644.1, ZP_06731146.1, ZP_06839371.1,
 ZP_07007312.1, ZP_07266194.1, ZP_07374050.1, ZP_07662787.1, ZP_07778196.1,
 ZP_07797983.1, ZP_08099459.1, ZP_08138203.1, ZP_08141719.1, ZP_08142973.1,
 20 ZP_08177102.1, ZP_08185821.1, ZP_08186468.1, ZP_08208888.1, ZP_08266590.1,
 ZP_08402041.1, ZP_08406891.1, ZP_08522175.1, ZP_08527488.1, ZP_08631252.1,
 ZP_08636687 and variants thereof.

The fatty acid reductase used according to the invention and preferably also other enzymes
 25 used according to the invention are recombinant enzymes. In a preferred embodiment, the term
 "recombinant", as used herein, is understood to mean that the nucleic acid molecule encoding
 the corresponding enzyme does not occur in the natural cell and/or it has been produced using
 gene technology methods. In a preferred embodiment, the term recombinant protein is used if
 the corresponding polypeptide is encoded by a recombinant nucleic acid. In a preferred
 30 embodiment, a recombinant cell, as used herein, is understood to mean a cell which has at
 least one recombinant nucleic acid or recombinant polypeptide. Methods suitable for producing
 recombinant molecules or cells are known to the person skilled in the art, for example those

described in Sambrook/Fritsch/Maniatis (1989): Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2nd edition. Recombinant enzymes are preferably overexpressed, for example by using pET or pGEX vector systems, which are known to the person skilled in the art.

5

With regard to the choice of organism, the whole-cell catalyst usable according to the invention is not subject to any restrictions, provided it is culturable, stable and amenable to possible modifications introducible by gene technology methods, for example methods for attenuating enzyme activities, an example being knock-outs. For instance, the cell can equally be a

10 prokaryotic cell or eukaryotic cell. In the case of a eukaryotic cell, particular preference is given to unicellular eukaryotes, especially yeasts such as *Saccharomyces cerevisiae*, *Candida tropicalis*, *Candida albicans* and *Pichia pastoris*. In the case of prokaryotic cells, the cell can, for example, be a bacterium selected from the group comprising *Magnetococcus*, *Mariprofundus*, *Acetobacter*, *Acetobacterium*, *Acidiphilium*, *Afipia*, *Ahrensia*, *Asticcacaulis*, *Aurantimonas*,

15 *Azorhizobium*, *Azospirillum*, *Bacillus*, *Bartonella*, *tribocorum*, *Beijerinckia*, *Bradyrhizobium*, *Brevundimonas*, *subvibrioides*, *Brucella*, *Caulobacter*, *Chelativorans*, *Citricella*, *Citromicrobium*, *Clostridium*, *Corynebacterium*, *Dinoroseobacter*, *Erythrobacter*, *Fulvimarina*, *Gluconacetobacter*, *Granulibacter*, *Hirschia*, *Hoeflea*, *Hyphomicrobium*, *Hyphomonas*, *Ketogulonicigenium*, *Labrenzia*, *Loktanela*, *Magnetospirillum*, *Maricaulis*, *Maritimibacter*,

20 *Mesorhizobium*, *Methylobacterium*, *Methylocystis*, *Methylosinus*, *Nitrobacter*, *Novosphingobium*, *Oceanibulbus*, *Oceanicaulis*, *Oceanicola*, *Ochrobactrum*, *Octadecabacter*, *Oligotropha*, *Paracoccus*, *Parvibaculum*, *Parvularcula*, *Pelagibaca*, *Phaeobacter*, *Phenylobacterium*, *Polymorphum*, *Pseudovibrio*, *Rhodobacter*, *Rhodomicrobium*, *Rhodopseudomonas*, *Rhodospirillum*, *Roseibium*, *Roseobacter*, *Roseomonas*, *Roseovarius*, *Ruegeria*, *Sagittula*,

25 *Silicibacter*, *Sphingobium*, *Sphingomonas*, *Sphingopyxis*, *Starkeya*, *Sulfitobacter*, *Thalassibium*, *Xanthobacter*, *Zymomonas*, *Agrobacterium*, *Rhizobium*, *Sinorhizobium*, *Anaplasma*, *Ehrlichia*, *Neorickettsia*, *Orientia*, *Rickettsia*, *Wolbachia*, *Bordetella*, *Burkholderia*, *Cupriavidus*, *Taiwanensis*, *Lautropia*, *Limnobacter*, *Polynucleobacter*, *Ralstonia*, *Chromobacterium*, *Eikenella*, *corrodens*, *Basfia*, *Kingella*, *Laribacter*, *Lutiella*, *Neisseria*,

30 *Simonsiella*, *Achromobacter*, *Acidovorax*, *Alicyclophilus*, *Aromatoleum*, *Azoarcus*, *Comamonas*, *Dechloromonas*, *Delftia*, *Gallionella*, *Herbaspirillum*, *Herminiimonas*, *Hylemonella*, *Janthinobacterium*, *Leptothrix*, *Methylibium*, *Methylobacillus*, *Methylophilales*, *Methyloversatilis*, *Methylovorus*, *Nitrosomonas*, *Nitrosospira*, *Oxalobacter*, *Parasutterella*, *Polaromonas*, *Polaromonas*, *Pusillimonas*, *Rhodoferax*, *Rubrivivax*, *Sideroxydans*, *Sutterella*, *wadsworthensis*,

Taylorella, *Thauera*, *Thiobacillus*, *Thiomonas*, *Variovorax*, *Verminephrobacter*,
Anaeromyxobacter, *Bdellovibrio*, *bacteriovorus*, *Bilophila*, *Desulfarculus*, *Desulfatibacillum*,
Desulfobacca, *Desulfobacterium*, *Desulfobulbus*, *Desulfococcus*, *Desulfohalobium*,
Desulfitobacterium, *Desulfomicrobium*, *Desulfonatronospira*, *Desulfotalea*, *Desulfovibrio*,
5 *Desulfuromonas*, *Geobacter*, *Haliangium*, *Hipaea*, *Lawsonia*, *Myxococcus*, *Pelobacter*,
Plesiocystis, *Sorangium*, *Stigmatella*, *Syntrophobacter*, *Syntrophus*, *Arcobacter*, *Caminiibacter*,
Campylobacter, *Helicobacter*, *Nitratifactor*, *Nitratiruptor*, *Sulfuricurvum*, *Sulfurimonas*,
Sulfurospirillum, *Sulfurovum*, *Wolinella*, *Buchnera*, *Blochmannia*, *Hamiltonella*, *Regiella*, *Riesia*,
Citrobacter, *Cronobacter*, *Dickeya*, *Edwardsiella*, *Enterobacter*, *Erwinia*, *Escherichia*, *Klebsiella*,
10 *Pantoea*, *Pectobacterium*, *Proteus*, *Providencia*, *Rahnella*, *Salmonella*, *Serratia*, *Shigella*,
Sodalis, *Wigglesworthia*, *Glossina*, *Xenorhabdus*, *Yersinia*, *Acidithiobacillus*, *Acinetobacter*,
Aeromonas, *Alcanivorax*, *Alkalilimnicola*, *Allochromatium*, *Alteromonadales*, *Alteromonas*,
Baumannia, *Beggiatoa*, *Bermanella*, *Carsonella*, *Ruthia*, *Vesicomysocius*, *Cardiobacterium*,
Chromohalobacter, *Colwellia*, *Congregibacter*, *Coxiella*, *Dichelobacter*, *Endoriftia*,
15 *Enhydrobacter*, *Ferrimonas*, *Francisella*, *Glaciecola*, *Hahella*, *Halomonas*, *Halorhodospira*,
Halothiobacillus, *Idiomarina*, *Kangiella*, *Legionella*, *Marinobacter*, *Marinomonas*, *Methylobacter*,
Methylococcus, *Methylomicrobium*, *Methylophaga*, *Moraxella*, *Moritella*, *Neptuniibacter*,
Nitrococcus, *Pseudoalteromonas*, *Psychrobacter*, *Psychromonas*, *Reinekea*, *Rickettsiella*,
Saccharophagus, *Shewanella*, *Succinatimonas*, *Teredinibacter*, *Thioalkalimicrobium*,
20 *Thioalkalivibrio*, *Thiomicrospira*, *Tolomonas*, *Vibrionales*, *Actinobacillus*, *Aggregatibacter*,
Gallibacterium, *Haemophilus*, *Histophilus*, *Mannheimia*, *Pasteurella*, *Azotobacter*, *Cellvibrio*,
Pseudomonas, *Aliivibrio*, *Grimontia*, *Photobacterium*, *Photobacterium*, *Vibrio*,
Pseudoxanthomonas, *Stenotrophomonas*, *Xanthomonas*, *Xylella*, *Borrelia*, *Brachyspira*,
Leptospira, *Spirochaeta*, *Treponema*, *Hodgkinia*, *Puniceispirillum*, *Liberibacter*, *Pelagibacter*,
25 *Odyssella*, *Accumulibacter*, more particularly *B. subtilis*, *B. megaterium*, *C. glutamicum*, *E. coli*,
Pseudomonas sp., *Pseudomonas fluorescens*, *Pseudomonas putida*, *Pseudomonas stutzeri*,
Acinetobacter sp., *Burkholderia* sp., *Burkholderia thailandensis*, cyanobacteria, *Klebsiella* sp.,
Klebsiella oxytoca, *Salmonella* sp., *Rhizobium* sp. and *Rhizobium meliloti*. In a particularly
preferred embodiment, the cell is an enterobacterium, most preferably *Escherichia coli*.

30

It is advantageous when the whole-cell catalyst according to the invention comprises not only
the fatty acid reductase, phosphopantetheinyl transferase and the transaminase, but also an
alanine dehydrogenase in order to regenerate from inorganic nitrogen-containing molecules the
alanine consumed by the transaminase during the amination of the terminal aldehyde group. In

a preferred embodiment, the term "alanine dehydrogenase", as used herein, is understood to mean an enzyme which catalyses the conversion of L-alanine with consumption of water and NAD⁺ to pyruvate, ammonia and NADH and the reverse reaction. In a particularly preferred embodiment, the alanine dehydrogenase is selected from the group of alanine dehydrogenases

5 comprising the amino acid sequence of the alanine dehydrogenase from *Bacillus subtilis* (database code L20916), *Rhizobium leguminosarum* (database code CP001622), *Vibrio proteolyticus* (database code AF070716), *Mycobacterium tuberculosis* (database code X63069), *Enterobacter aerogenes* (database code AB013821), EGR93259.1, YP_003654745.1, YP_003651439.1, YP_003637111.1, YP_003631815.1, YP_001327051.1, YP_001262560.1,

10 YP_886996.1, YP_882850.1, YP_704410.1, YP_703508.1, ZP_08624689.1, YP_001230376.1, P17557.1, P17556.1, CCB94892.1, CCB73698.1, YP_001168635.1, YP_004668736.1, YP_004569425.1, YP_003513168.1, YP_004561169.1, ZP_08554945.1, YP_400777.1, ZP_08311476.1, ZP_08310170.1, ZP_08267322.1, ZP_08263846.1, ZP_07898723.1, YP_149301.1, YP_148605.1, YP_004340432.1, EFT09946.1, EFS80513.1, EFS51332.1,

15 EFS42459.1, YP_003060895.1, YP_003059033.1, ZP_03305373.1, YP_847214.1, YP_004095847.1, YP_003338282.1, YP_003337256.1, YP_355846.1, YP_253131.1, ZP_08197563.1, ZP_08196283.1, ADW06447.1, YP_734091.1, NP_372233.1, NP_102173.1, ZP_08170259.1, EGD36706.1, EGD32748.1, ZP_08155540.1, YP_004142849.1, YP_002417649.1, YP_001301040.1, YP_002992892.1, YP_081348.1, YP_080482.1,

20 YP_002476349.1, ZP_08115025.1, ZP_08114403.1, YP_003552869.1, YP_002358112.1, YP_575010.1, YP_477594.1, YP_474564.1, YP_130399.1, YP_129373.1, YP_123314.1, NP_810467.1, NP_646469.1, NP_626044.1, NP_391071.1 (encoded by SEQ ID NO: 11), ZP_08086822.1, ZP_08084776.1, ZP_08083119.1, ZP_08020768.1, ZP_08013590.1, ZP_08011832.1, YP_003783744.1, YP_002781576.1, YP_002780533.1, ZP_02195873.1,

25 NP_797482.1, ZP_07645051.1, ZP_07643260.1, ZP_06611917.1, AAT40119.1, ZP_07864946.1, YP_004068409.1, YP_002796203.1, YP_002774420.1, YP_003600348.1, YP_003599946.1, YP_003565624.1, YP_003565223.1, YP_335198.1, YP_423850.1, YP_155059.1, ZP_07843538.1, ZP_07841226.1, ZP_06928932.1, ZP_05692073.1, ZP_05687006.1, ZP_04867480.1, YP_775531.1, CBE70214.1, ZP_07721182.1,

30 ZP_04302850.1, ZP_04298961.1, ZP_04287684.1, ZP_04277177.1, ZP_04248389.1, ZP_04235899.1, ZP_02159718.1, ZP_02152178.1, YP_003974610.1, YP_003546595.1, YP_002317127.1, ZP_07313778.1, ZP_07302778.1, ZP_07298850.1, CBK69442.1, YP_003413835.1, YP_003595089.1, ZP_06807811.1, YP_003582455.1, YP_003464731.1, YP_003496397.1, YP_003421918.1, CBL07274.1, CBK64956.1, YP_003508515.1,

AAL87460.1, AAC23579.1, AAC23578.1, AAC23577.1, ACU78652.1, YP_003471439.1, YP_003452777.1, ZP_06384971.1, ACY25368.1, ABC26869.1, AAP44334.1, EEZ80018.1, ZP_05110458.1, 1PJB_A, ZP_04717201.1, ZP_04689103.1, CAO90307.1, CAM75354.1, CAA44791.1, BAA77513.1, EGR96638.1, EGL90046.1, YP_004510847.1, ZP_08450330.1, 5 YP_003387804.1, YP_003058152.1, EFS74272.1, EFS67128.1, ZP_06844564.1, YP_826658.1, YP_001195249.1, YP_003095978.1, YP_469292.1, YP_004442054.1, YP_004461174.1, YP_004055616.1, YP_003576656.1, YP_003094537.1, YP_001295973.1, AEE71143.1, YP_004447480.1, YP_003761844.1, YP_040853.1, YP_003154888.1, YP_003142045.1, YP_002280953.1, NP_371963.1, NP_422368.1, EGC98966.1, EGC76398.1, 10 YP_004263661.1, YP_004252039.1, YP_679036.1, YP_499973.1, ZP_08054972.1, ZP_08053009.1, ZP_04067276.1, ZP_03968868.1, ZP_03963857.1, ZP_03933079.1, ZP_03497046.1, ZP_06668924.1, ZP_06667106.1, ZP_06324464.1, ZP_06196777.1, ZP_05114159.1, ZP_05083968.1, ZP_05070370.1, ZP_05030022.1, ZP_04673064.1, ZP_03517011.1, ZP_03505783.1, XP_001310698.1, ABK27691.1 and CAB59281.2 and 15 variants thereof. For the reaction catalysed by the alanine dehydrogenase, the presence is required of not only pyruvate, which is formed as part of the primary metabolism of any cell suitable as whole-cell catalyst, but also ammonium. The latter is typically provided in the form of inorganic nitrogen salts, for example ammonium salts, nitrates or the like. Preferably, an ammonium salt, for example ammonium chloride, is added to the aqueous reaction medium.

20

Furthermore, it is advantageous when the whole-cell catalyst according to the invention expresses an alkane hydroxylase and optionally further enzymes essential for the activity of the alkane hydroxylase, especially when a fatty acid having only one terminal carboxy function is used as substrate for producing a diamine. The alkane hydroxylase and/or an additionally 25 expressed alcohol dehydrogenase oxidize the terminal carbon atom then up to the aldehyde group, which can subsequently be aminated by the transaminase, or up to the carboxyl group, which is converted by an α -dioxygenase or the combination of fatty acid reductase and a phosphopantetheinyl transferase to a terminal aldehyde group, which can subsequently be aminated by the transaminase. In a preferred embodiment, the term "alkane hydroxylase", as 30 used herein, is understood to mean an enzyme which catalyses the hydroxylation of unsubstituted linear alkyl radicals comprising at least six, preferably twelve, carbon atoms.

According to the invention, numerous oxidation systems, as described in, inter alia, PCT/EP 2008/067447, are suitable as alkane hydroxylases. In a preferred embodiment, the alkane

hydroxylase is a cytochrome P450 monooxygenase of the CYP153 family. In a preferred embodiment, the term "cytochrome P450 monooxygenase of the CYP153 family" is understood to mean a cytosolic oxidase which is part of a 3-component system which further comprises a ferredoxin and a ferredoxin reductase, with an alkane binding site and the ability to hydroxylate alkanes. In a particularly preferred embodiment, it is an enzyme which has to at least 80, preferably 90, most preferably 95 or 99%, sequence identity to the cytochrome P450 monooxygenase of the CYP153 family from *Alcanivorax borkumensis* SK2 (database code YP_691921) or an enzyme which comprises a polypeptide sequence which has at least 80, preferably 90, most preferably 95 or 99%, sequence identity to the cytochrome P450 monooxygenase of the CYP153 family from *Alcanivorax borkumensis* SK2 (database code YP_691921) and moreover has alkane hydroxylase activity. As throughout this application, the stated database codes concern the NCBI (National Center for Biotechnology Information, Bethesda, USA) databases, specifically the version available online on 21 November 2012. In a preferred embodiment, the term "cytochrome P450 monooxygenase of the CYP153 family" is understood to mean a non-membrane-bound oxidase which includes a binding site for alkanes, unsubstituted linear alkyl radicals comprising at least five, preferably twelve, carbon atoms or monohydroxylated alkanes and the polypeptide chain of which comprises the motif LL(I/L)(V/I)GGNDTTRN. In a preferred embodiment, a "cytochrome P450 monooxygenase of the CYP153 family", as used herein, is a cytochrome P450 monooxygenase of the CYP153 family from *Alcanivorax borkumensis* SK2 (database code YP_691921) or a variant thereof which preferably has alkane hydroxylase activity.

For the optimal supply of the cytochrome P450 monooxygenase of the CYP153 family with electrons from the reducing agent, preferably NADH, it is preferred that the cell the alkane hydroxylase is expressed together with ferredoxin reductase that interacts functionally with it and ferredoxin that interacts functionally with it. These may be isolated polypeptides or, in the case of using a whole-cell catalyst, coexpressed polypeptides or polypeptides fused on the N- or C-terminus with the cytochrome P450 monooxygenase of the CYP153 family. Whether a ferredoxin reductase or a ferredoxin interact functionally with a given cytochrome P450 monooxygenase of the CYP153 family with one another can be readily established by the person skilled in the art by whether the reducing agent is oxidized more efficiently in the presence of an alkane substrate and the three polypeptides than when at least one of the three is absent. Alternatively, it is possible to use the enzyme assay described by Scheps, D., Malca, H., Hoffmann, B., Nestl, B. M., and Hauer, B. (2011) *Org. Biomol. Chem.*, 9, 6727, which, in the

case of functionally interacting polypeptides, exhibits a considerable increase in the reaction rate. In a particularly preferred embodiment, the cytochrome P450 monooxygenase of the CYP153 family, the ferredoxin and the ferredoxin reductase originate from the same organism. In a particularly preferred embodiment, they are the ferredoxin reductase from *Alcanivorax*
 5 *borkumensis* SK2 (database code YP_691923) or a variant thereof, the ferredoxin from *Alcanivorax borkumensis* SK2 (database code YP_691920) or a variant thereof and the cytochrome P450 monooxygenase of the CYP153 family from *Alcanivorax borkumensis* SK2 (database code YP_691921) or a variant thereof.

- 10 In a further preferred embodiment, the alkane hydroxylase is an AlkB monooxygenase. AlkB represents an oxidoreductase which initially became known from the AlkBGT system of *Pseudomonas putida* Gpo1, and which is dependent on two further polypeptides, AlkG and AlkT. AlkT is characterized as a FAD-dependent rubredoxin reductase, which transfers electrons from NADH to AlkG. AlkG is a rubredoxin, an iron-containing redox protein which
 15 functions as a direct electron donor to AlkB. In a preferred embodiment, the term "AlkB monooxygenase" is a polypeptide having a sequence homology of at least 75, 80, 85, 90, 92, 94, 96, 98 or 99% – specified in order of increasing preference – to the sequence of the AlkB of *Pseudomonas putida* Gpo1 (database code: CAB54050.1; this database code originates like all others from the prior art used in the application, namely from the NCBI database, more
 20 precisely the release available online on 15th October 2012) having the capability to oxidize alkanes. In a particularly preferred embodiment, the AlkB monooxygenase is an oxidoreductase which functionally interacts with the AlkG (CAB54052.1) and AlkT (CAB54063.1) polypeptides from *Pseudomonas putida* Gpo1 and oxidizes alkanes. For the optimal supply of the AlkB alkane hydroxylase with electrons, it is preferred that the cell the alkane hydroxylase is
 25 expressed together with auxiliary proteins that interact functionally with it, preferably AlkG and/or AlkT or variants of each, and in a particularly preferred embodiment they are again AlkG (CAB54052.1) and AlkT (CAB54063.1) polypeptides from *Pseudomonas putida* Gpo1.

- When using a whole-cell catalyst, the problem can arise that a substrate has to be brought into
 30 contact with an intracellularly localized enzyme so that it results in the desired reaction. In the case of long-chain alkanes and derivatives thereof, it is preferred that the whole-cell catalyst has a polypeptide of the AlkL family. AlkL is a membrane protein from *Pseudomonas putida*, which protein can import long-chain fatty acids and derivatives thereof into bacterial cells. In a preferred embodiment, a "polypeptide of the AlkL family", as used herein is a polypeptide which,

over a length of 230 successive amino acids, has an at least 80, preferably 90, more preferably 90% sequence identity to AlkL from *Pseudomonas putida* (database code CAB69081) or a variant of AlkL from *Pseudomonas putida* and preferably the ability to assist the import of long-chain alkanes into the inside of a cell. In a further embodiment, a "polypeptide of the AlkL family", as used herein, is a polypeptide located in the outer membrane of a Gram-negative bacterium and which has the sequence motif DXWAPAXQ(V/A)GXR, where X is a proteinogenic amino acid, and preferably is additionally AlkL from *Pseudomonas putida* (database code CAB69081) or a variant thereof. Examples of members of the AlkL family include AlkL from *Pseudomonas putida* (database code CAB69081), *Marinobacter aquaeolei* VT8 (database code YP_957722), *Oceanicaulis alexandrii* HTCC2633 (database code ZP_00953584), *Marinobacter manganoxydans* Mnl7-9 (database code ZP_09158756), *Caulobacter* sp. K31 (database code YP_001672217), *Pseudomonas oleovorans* (database code Q00595) and variants thereof.

The teaching of the present invention can be carried out by not only using macromolecules having the exact amino acid or nucleic acid sequence to which reference is made herein or by not only using a cell having reduced activity, relative to the respective wild type, of a polypeptide having the exact amino acid sequence to which reference is made herein, but also by using a variant of such macromolecules or a cell having a reduced activity, relative to the respective wild type of the respective cell, of a variant of the polypeptide, which variant can be obtained by deletion, addition or substitution of one or more than one amino acid or nucleic acid. In a preferred embodiment, the term "variant" of a nucleic acid sequence or amino acid sequence, used hereinafter synonymously and exchangeably with the term "homologue", as used herein, means another nucleic acid or amino acid sequence comprising or representing a sequence which, with respect to the corresponding original wild-type nucleic acid or amino acid sequence, has a homology, used here synonymously with identity, of 70, 75, 80, 85, 90, 92, 94, 96, 98, 99% or greater, wherein preferably amino acids other than the ones forming the catalytically active site or essential for the structure or folding are deleted or substituted or are merely conservatively substituted, for example a glutamate instead of an aspartate or a leucine instead of a valine. The prior art describes algorithms, which may be used to calculate the degree of homology of two sequences, e.g. Arthur Lesk (2008), Introduction to Bioinformatics, 3rd edition. In a further more preferred embodiment of the present invention, the variant of an amino acid or nucleic acid sequence, preferably in addition to the sequence homology mentioned above, has substantially the same enzymatic activity of the wild-type molecule and/or of the original

molecule. For example, a variant of an enzymatically active polypeptide protease has the same, or substantially the same, proteolytic activity as the polypeptide enzyme, i.e. the capability to catalyse the hydrolysis of a peptide bond. In a particular embodiment, the term "substantially the same enzymatic activity" means an activity, with respect to the substrates of the wild-type polypeptide, which clearly lies above the background activity or/and differs from the K_M and/or k_{cat} values by less than 3, more preferably 2, even more preferably one order of magnitude, which the wild-type polypeptide exhibits with respect to the same substrates. In a further preferred embodiment, the term "variant" of a nucleic acid or amino acid sequence includes at least one active part or fragment of the nucleic acid or amino acid sequence. In a further preferred embodiment, the term "active part", as used herein, means an amino acid sequence or a nucleic acid sequence which has a smaller amino acid sequence than the full length of the amino acid sequence or encodes a smaller amino acid sequence than the full length of the amino acid sequence, where the amino acid sequence or the encoded amino acid sequence with the smaller length than the wild-type amino acid sequence has substantially the same enzymatic activity as the wild-type polypeptide or a variant thereof, for example as protease. In a particular embodiment, the term "variant" of a nucleic acid encompasses a nucleic acid, the complementary strand of which, preferably under stringent conditions, binds to the wild-type nucleic acid. The stringency of the hybridization reaction is readily determinable by those skilled in the art and depends in general on the length of the probe, the washing temperatures and the salt concentration. Generally, longer probes require higher temperatures for the hybridization, whereas shorter probes work at lower temperatures. Whether hybridization takes place depends in general on the capability of the denatured DNA to anneal to complementary strands which are present in its environment, specifically below the melting temperature. The stringency of hybridization reaction and corresponding conditions are described in more detail in F M Ausubel (1995), Current Protocols in Molecular Biology. John Wiley & Sons, Inc. Instructions for identifying DNA sequences by means of hybridization can be found by the person skilled in the art inter alia in the handbook "The DIG System Users Guide for Filter Hybridization" from Boehringer Mannheim GmbH (Mannheim, Germany, 1993) and in Liebl *et al.* (International Journal of Systematic Bacteriology 41: 255-260 (1991)). The hybridization takes place in a preferred embodiment under stringent conditions, i.e. only hybrids are formed in which probe and target sequence, i.e. the polynucleotides treated with the probe, are at least 70% identical. It is known that the stringency of the hybridization including the washing steps is influenced and/or determined by varying the buffer composition, the temperature and the salt concentration. The hybridization reaction is generally carried out at a relatively low stringency

compared with the washing steps (Hybaid Hybridisation Guide, Hybaid Limited, Teddington, UK, 1996). For the hybridization reaction, for example, a buffer corresponding to 5x SSC buffer can be used at a temperature of about 50°C - 68°C. In this connection, probes can also hybridize to polynucleotides which have less than 70% identity to the sequence of the probe. Such hybrids

5 are less stable and are removed by washing under stringent conditions. This can be achieved for example by lowering the salt concentration to 2x SSC and optionally subsequently 0.5x SSC (The DIG System User's Guide for Filter Hybridisation, Boehringer Mannheim, Mannheim, Germany, 1995), in which case a temperature of, increasing in order of preference, about 50°C - 68°C, about 52°C - 68°C, about 54°C - 68°C, about 56°C - 68°C, about 58°C - 68°C, about

10 60°C - 68°C, about 62°C - 68°C, about 64°C - 68°C, about 66°C - 68°C is established. Temperature ranges from about 64°C - 68°C or about 66°C - 68°C are preferred. It is optionally possible to reduce the salt concentration down to a concentration corresponding to 0.2 x SSC or 0.1 x SSC. By means of a stepwise increase in the hybridization temperature in steps of about 1 - 2°C from 50°C to 68°C, polynucleotide fragments can be isolated which, for example in the

15 order of increasing preference, have at least 70% or at least 80% or at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to the sequence of the nucleic acid molecule used. Further instructions relating to the hybridization are commercially available in the form of so-called kits (e.g. DIG Easy Hyb from Roche Diagnostics GmbH, Mannheim, Germany, Catalogue No. 1603558). In a

20 preferred embodiment, the term "variant" of a nucleic acid, as used herein, encompasses any nucleic acid sequence which encodes the same amino acid sequence as the original nucleic acid or a variant of this amino acid sequence in the context of the degeneracy of the genetic code.

25 In a preferred embodiment, the cell used according to the invention has a reduced activity, with respect to its wild type, of at least one enzyme which catalyses one of the reactions of the β -oxidation of fatty acids, and preferably this is an enzyme from the group comprising fatty acid-CoA ligase, acyl-CoA dehydrogenase, 2,4-dienoyl-CoA reductase, enoyl-CoA hydratase and 3-ketoacyl-CoA thiolase, a fatty acid importer or variants thereof. The β -oxidation of fatty acids is a

30 widespread metabolic pathway which equally permits prokaryotic and eukaryotic organisms to oxidize fatty acids and to make the chemical energy present therein available to metabolism. In the broader sense, it starts with the uptake of a fatty acid into the cell. There, if the conditions require it, the fatty acid is firstly oxidized at the β -position of the CoA-fatty acid ester by an acyl-CoA dehydrogenase, in the case of *E. coli* FadE. A similar molecule can alternatively also be

formed from a double-unsaturated fatty acid by reduction by means of a 2,4-dienoyl-CoA reductase, in the case of *E. coli* FadH. A multifunctional enzyme, the enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase, in the case of *E. coli* FadB, then catalyses the hydration with the formation of the secondary alcohol and its subsequent oxidation to the ketone. In the last

5 step, a 3-ketoacyl-CoA thiolase, in the case of *E. coli* FadA, catalyses the cleavage of the ketoacyl-CoA, with the result that acetyl-CoA and a CoA ester of the fatty acid that is two carbon atoms shorter compared to the starting molecule are released. If the latter is not likewise acetyl-CoA, it can be fed again into the β -oxidation cycle and be shortened via oxidation. Also involved

10 in the regulation of the β -oxidation of fatty acids is FadR, a regulator of the Fad operon, which includes the genes required for the degradation of fatty acids, without FadR appearing to catalyse a reaction of the β -oxidation. In a preferred embodiment, the term "enzyme which catalyses one of the reactions of the β -oxidation of fatty acids" is understood as meaning any enzyme which interacts directly with the fatty acid substrate or a molecule formed therefrom on the pathway to the acetyl-CoA, preferably recognizes it as substrate, and catalyses its

15 conversion to a metabolic product lying closer to the acetyl-CoA on this degradation pathway, preferably including the fatty acid importer, which effects the uptake of the fatty acid into the cell. For example, according to the preceding definition, these enzymes include acyl-CoA dehydrogenase, since it interacts with the fatty acid-CoA ester and catalyses its conversion to the enoyl-CoA, which lies closer to the acetyl-CoA on the metabolic pathway of β -oxidation than

20 the fatty acid-CoA ester. In a particularly preferred embodiment, the term "enzyme which catalyses one of the reactions of the β -oxidation of fatty acids", as used herein, is understood as meaning any enzyme from the group which comprises the gene products FadA, FadB, FadD, FadL and FadE from *E. coli* and/or their variants or homologues from other organisms. The gene products FadA, FadB, FadD, FadL and FadE from *E. coli* as well as variants and

25 homologues from numerous other biotechnologically useful organisms and their nucleic acid and polypeptide sequences are described in the prior art, for example FadA under accession number AP009048.1, FadB under accession number BAE77457.1, FadD under accession number BAA15609.1, and FadE under accession number BAA77891.2. The prior art discloses numerous assays which are suitable specifically for measuring the activity of enzymes which

30 catalyse one of the reactions of the β -oxidation of fatty acids, for example in K Kameda & W D Nunn (1981) *J. Biol. Chem.* 256, 5702-5707, Hi Marrakchi, W E DeWolf, C Quinn, J West, B J Polizzi, C Y So et al. (2003) *Biochem. J.* 370, 1055-1062, Lobo *et al.* (2001) and X Yu, T Liu, F Zhu, and C Khosla (2011) *PNAS*, *electronic publication prior to print*.

For the efficiency of the whole-cell catalyst according to the invention, it is advantageous when the substrate to be converted, preferably the carboxylic acid or dicarboxylic acid or a monoester thereof, can easily enter into contact with the enzymes which are required according to the invention and which are located inside the whole-cell catalyst. Therefore, it is critical that the substrate can reach the interior of the cell. To facilitate this, it is preferred that the whole-cell catalyst expresses a fatty acid importer, in the case of a bacterial, more particularly Gram-negative, whole-cell catalyst, particularly preferably the fatty acid importer FadL (database code: BAA16205.1) or a variant, preferably in a concentration and with an activity which is increased with respect to the activity of the wild type of the corresponding whole-cell catalyst. Increasing the activity of a polypeptide with respect to the wild type of the cell can be achieved via various routes routinely accessible to the person skilled in the art, for example the incorporation of additional copies, functionally linked to a promoter, of the nucleotide sequence encoding the polypeptide or the exchange of the natural promoter for a stronger promoter.

It has been found that, according to the invention, the amines and diamines are produced in a higher yield and purity when the background of enzymes expressed endogenously in the whole-cell catalyst is optimized in such a way to reduce or switch off the activity of endogenous enzymes which degrade reactants, intermediates or products of the process according to the invention or using the cell according to the invention, preferably methyl esters of ω -aminocarboxylic acids, ω -hydroxycarboxylic acids, ω -oxocarboxylic acids and dicarboxylic acids, on metabolic pathways or otherwise modify them, leading away from the development of the desired product. Against this background, it may be advantageous when the whole-cell catalyst according to the invention is a cell having, with respect to its wild type, a reduced activity of the esterase BioH [database code YP_492020.1] or a variant thereof. Such cells having reduced BioH activity, the production thereof and assays to determine activity are described in the European patent application EP 12007663.3.

If the carboxylic acid, dicarboxylic acid or monoester thereof used are mixtures of compounds in which the terminal carboxy groups are present to a high degree, preferably to an extent of at least 50, 60, 70, 80, 90, 95 or 99%, in the form of an ester, for example because of the better availability of these substrates or the toxicity of free carboxylic acids or dicarboxylic acids, the monoester can be provided by partial or complete hydrolysis of completely esterified dicarboxylic acids and the free carboxylic acid by partial or complete hydrolysis of completely

esterified carboxylic acids. In this case, it is advantageous to increase the capacity of the cell in relation to ester hydrolysis by overexpression of a suitable esterase. To this end, in a preferred embodiment, the activity of the ester hydrolase BioH or a variant thereof is increased with respect to the wild type of the whole-cell catalyst used, particularly preferably by overexpression. The corresponding monoester and/or the unesterified carboxylic acid or dicarboxylic acid is then provided *in situ* by ester hydrolysis. The partial or complete hydrolysis of a completely esterified dicarboxylic acid can also be effected by chemically catalysed hydrolysis, for example at low pH levels.

- 10 The whole-cell catalyst according to the invention can be preferably used in a process for converting a carboxylic acid or dicarboxylic acid or a monoester thereof to the corresponding amine or diamine, wherein the carboxylic acid or dicarboxylic acid or the monoester thereof is a compound of the formula (I)



- where R^1 is selected from the group comprising -H and $COOR^3$, where R^2 and R^3 are each independently selected from the group comprising H, methyl, ethyl and propyl, with the proviso that at least one of the radicals R^2 and R^3 is H, where A is an unbranched, branched, linear, cyclic, substituted or unsubstituted hydrocarbon group having at least four carbon atoms. In a preferred embodiment, A is a structure of the formula $-(CH_2)_n-$, where n is preferably 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30. In a preferred embodiment, the carboxylic acid or dicarboxylic acid is lauric acid or ω -carboxylauric acid. In a further most preferred embodiment, the carboxylic acid is a carboxylic acid of the formula $CH_3-(CH_2)_n-COOH$, where n is preferably 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30, preferably hexanoic acid or decanoic acid. In a further most preferred embodiment, the carboxylic acid or dicarboxylic acid is a dicarboxylic acid of the formula $HOOC-(CH_2)_n-COOH$, where n is preferably 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30, preferably ω -carboxyhexanoic acid or ω -carboxydecanoic acid. In a further most preferred embodiment, the carboxylic acid or dicarboxylic acid is ω -carboxytetradecanoic acid. Accordingly, the amine or diamine produced according to the invention is preferably a compound of the formula $CH_3-(CH_2)_n-NH_2$ or $NH_2-(CH_2)_n-NH_2$, where n is in each case preferably 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30.

With respect to the carboxylic acid or dicarboxylic acid or the monoester thereof and to any chemical compound described in this application, it is the case that the respective specified formula encompasses all salts, protonated or deprotonated, of the respective compound. For example, the lauric acid encompasses not only the protonated form, but also the salt laureate with all cations, for example sodium laureate.

It is a requirement of the process according to the invention that the enzymes used for the process according to the invention, optionally provided in the form of the whole-cell catalyst according to the invention, be contacted with the carboxylic acid or dicarboxylic acid or the monoester thereof in an aqueous solution. In a preferred embodiment, the term "contacting", as used herein, is understood to mean that the particular enzyme gets into direct contact with its substrate, more particularly without physical barriers such as impermeable membranes or the like being interposed. In the simplest case, contacting occurs by the substrate being added to an aqueous solution in which the enzyme or the whole-cell catalyst is situated.

Suitable for carrying out the teaching according to the invention is a reaction mixture comprising the whole-cell catalyst 8 according to the invention in aqueous solution and a carboxylic acid or dicarboxylic acid or a monoester thereof of the formula (I), where R^1 is selected from the group comprising $-H$ $COOR^2$, where R^2 and R^3 are each independently selected from the group comprising H, methyl, ethyl and propyl, with the proviso that at least one of the radicals R^2 and R^3 is H, where A is an unbranched, branched, linear, cyclic, substituted or unsubstituted hydrocarbon group having at least four carbons, preferably the formula $-(CH_2)_n-$, where n is at least 4, particularly preferably at least 10. The aqueous solution must, for example with respect to composition, pH and temperature, be of such a nature that said solution supports, at least for a certain period, the viability or at least the catalytic capability of the whole-cell catalyst. The person skilled in the art knows numerous aqueous culture media which are suitable as aqueous solution and which are suitable for maintaining or culturing cells, more particularly cells of biotechnological importance. These include, equally, complete media such as LB media, minimal media such as M9 media and also selective media, for example those which have a high salt concentration and therefore only permit the growth of halophilic or at least halotolerant organisms. In a preferred embodiment, the term "aqueous culture medium", as used herein, is understood to mean a water-based reaction medium which, with respect to all relevant factors, in particular pH, salt content and temperature, is of such a nature that it maintains or promotes

the viability of cells present therein, preferably microorganisms, and both aqueous culture medium and hydrophobic organic phase are present in liquid form. The temperature requirements of various biotechnologically important cells can be found in microbiology and molecular biology textbooks, for example Fuchs/Schlegel, 2008. In a preferred embodiment, the pH of the aqueous culture medium at the time point of contacting is between 4 and 9, more preferably between 4.5 and 8.5, most preferably between 6.5 and 7.5. In a further preferred embodiment, the temperature is between 0 and 45°C, more preferably between 15 and 40°C, most preferably between 20 and 37°C. The reaction mixture is typically present in a fermenter. Any reaction vessel which can be sterilized, preferably autoclaved, and allows the culturing of the whole-cell catalyst, aeration and control of the reaction conditions, for example the oxygen content and the temperature, can act as fermenter.

In a preferred embodiment, the reaction mixture comprises, in addition to the aqueous solution, a hydrophobic organic phase. This can comprise an organic solvent and/or a hydrophobic liquid cation exchanger for removing the ω -amino fatty acid from the aqueous solution. Suitable solvents and cation exchangers are described in EP11191520.3.

The present invention is more particularly described by the following figures and non-limiting examples from which further features, embodiments, aspects and advantages of the present invention may be discerned.

Figure 1: Detection of monoamines and diamines in the fermentation broth of the strain *E.coli* W3110 pACYC{Placuv5}[carA_Ms-npt_Noc] / pJ281_alaDH_B.s._TA_C.v.(ct) after a 21.75 h process time.

Example 1

Producing an expression vector for the expression of the genes MSMEG_2956 from *Mycobacterium smegmatis* and *npt* from *Nocardia* sp.

To produce vectors for the coexpression of MSMEG_2956 (*carA*, SEQ ID No. 1) from *Mycobacterium smegmatis* encoding a fatty acid reductase (YP_887275.1) and with *npt* (SEQ ID No. 2) from *Nocardia* sp. encoding a phosphopantetheinyl transferase (ABI83656.1) which phosphopantetheinylates the fatty acid reductase, both genes were amplified by means of PCR with insertion of homologous regions for recombinant cloning. In this connection, genomic DNA

from the donor organism for the amplification of the gene MSMEG_2956 and a synthesized DNA fragment for the amplification of the gene *npt* served as template. The genes are under the control of a *lacuv5* promoter (SEQ ID No. 3), which was likewise amplified by means of PCR proceeding from an available vector with insertion of homologous regions for the recombinant cloning.

In this connection, the following oligonucleotides were used:

Plac_H1_fw: 5'-TTATGCGACTCCTGCTGGCTATGGTGGGATTTCC-3' (SEQ ID Nr. 4)

Plac_H2_rv: 5'-GATCGTCATATGCCACTCTCCTTGGTTCC-3' (SEQ ID Nr. 5)

10 carA_H2_fw: 5'-TGGCATATGACGATCGAAACGCGCG-3' (SEQ ID Nr. 6)

carA_H3_rv: 5'-TCCTTCTCTTACAGCAATCCGAGCATCT-3' (SEQ ID Nr. 7)

npt_H3_fw: 5'-GCTGTAAGAGAAGGAGTTCTATCATGATCGAG-3' (SEQ ID Nr. 8)

npt_H4_rv: 5'-GCAGCCTAGGTTAATTTATCAGGCGTACGCGATCG-3' (SEQ ID Nr. 9)

15

The following parameters were used for the PCR for the amplification of the *P_{lacuv5}* and the gene *npt*: 1 x: initial denaturation, 98°C, 0:30 min; 35 x: denaturation, 98°C, 0:10 min, annealing, 55°C, 0:20 min; elongation, 72°C, 0:15 min; 1 x: terminal elongation, 72 °C, 10 min. For the amplification of the gene MSMEG_2956, the following parameters were used: 1 x: initial denaturation, 98°C, 0:30 min; 35 x: denaturation, 98°C, 0:10 min, annealing, 65°C, 0:20 min; elongation, 72°C, 1 min; 1 x: terminal elongation, 72 °C, 10 min. For the amplification, the Phusion™ High-Fidelity Master Mix from New England Biolabs (Frankfurt) was used according to the recommendations from the manufacturer. In each case, 50 µl of the PCR reactions were then resolved on a 1% strength TAE agarose gel. The PCR, the agarose gel electrophoresis, ethidium bromide staining of the DNA and determination of the PCR fragment sizes were performed in the manner known to the person skilled in the art. In all cases, PCR fragments of the expected size could be amplified. These were 325 base pairs for *P_{lacuv5}*, 3.5 kilobase pairs for MSMEG_2956 and 718 base pairs for *npt*. To isolate the DNA from the agarose gel, the target DNA was cut out of the gel using a scalpel and purified using the *QiaQuick Gel extraction Kit* in accordance with the manufacturer's instructions (Qiagen, Hilden). The purified PCR products were cloned into an *Eco*NI- and *Pac*I-cut pACYCDuet-1 vector (Merck, Darmstadt) by means of recombination using the Geneart® Seamless Cloning and Assembly Kit in accordance with the manufacturer's instructions (Life Technologies, Carlsbad, CA, USA). Chemically competent *E.coli* DH10β (New England Biolabs, Frankfurt) were transformed in the manner

20
25
30

known to the person skilled in the art. The correct insertion of the target genes was checked by restriction analysis and the authenticity of the inserted genes confirmed by DNA sequencing. The finished expression vector was referred to as pACYC{Placuv5}[carA_Ms-npt_Noc] (SEQ ID No. 10).

5

Example 2

Producing an expression vector for the coexpression of the genes *ald* from *Bacillus subtilis* and Cv2025 from *Chromobacterium violaceum*

- 10 To produce an *E. coli* expression vector for the genes *ald* (SEQ ID No. 11) from *Bacillus subtilis* encoding an alanine dehydrogenase (NP_391071.1) and Cv_2025 (SEQ ID No. 12) from *Chromobacterium violaceum* encoding a transaminase (NP_901695.1), the gene *ald* from *Bacillus subtilis* was, in exchange for the gene *ald* from *Bacillus sphaericus*, cloned into the *E. coli* expression vector pJ281_alaD_Bsp_TA_C.v.(ct) (sequence and production, cf. example 1
15 in WO/2013/024114 and SEQ ID No. 17 listed therein). The gene *ald* from *Bacillus subtilis* was amplified by PCR from chromosomal DNA from the strain *Bacillus subtilis* str. 168. In this connection, the following oligonucleotides were used:

- alaDH_pCR22_fw: 5'-ATGATCATAGGGGTTCCTAAAGAG-3'
20 (SEQ ID No. 13)
alaDH_pCR22_rev: 5'-TTAAGCACCCGCCACAGATG-3'
(SEQ ID No. 14)

- The following parameters were used for the PCR: 1 x: initial denaturation, 98°C, 0:30 min; 35 x:
25 denaturation, 98°C, 0:10 min, annealing, 65°C, 0:30 min; elongation, 72°C, 0:20 min; 1 x:
terminal elongation, 72°C, 10 min. For the amplification, the Phusion™ High-Fidelity Master Mix from New England Biolabs (Frankfurt) was used according to the recommendations from the manufacturer. In each case, 50 µl of the PCR reactions were then resolved on a 1% strength TAE agarose gel. The PCR, the agarose gel electrophoresis, ethidium bromide staining of the
30 DNA and determination of the PCR fragment sizes were performed in the manner known to the person skilled in the art. The PCR fragment showed the expected size of 1137 base pairs and was purified from the PCR volume using the Quick PCR Purification Kit from Qiagen (Hilden) in accordance with the information from the manufacturer. For the ligation of the PCR product to the vector, 5'-phosphates were attached to the PCR product using the polynucleotide kinase

(New England Biolabs, Frankfurt). In this connection, the recommendation from the manufacturer was followed.

The vector was digested with the restriction endonucleases *HindIII* and *NdeI*, and as a result, the gene present, *Bacillus sphaericus ald*, was removed. The restriction digest volume was resolved on a 1% strength TAE agarose gel. It was possible to identify two bands of sizes 5696 bp and 1124 bp. To isolate the vector DNA from the agarose gel, the DNA band of 5696 bp was isolated from the gel using a scalpel and purified using the Quick Gel Extraction Kit from Qiagen (Hilden) in accordance with the information from the manufacturer. To generate blunt ends, the 5'-overhangs of the purified vector DNA were filled using the Klenow fragment of DNA polymerase I (New England Biolabs, Frankfurt). In this connection, the information from the manufacturer was followed. The DNA fragment *Bacillus subtilis ald* with 5'-phosphate residues was ligated into the vector having blunt ends. The finished *E. coli* expression vector was referred to as pJ281_alaDH_B.s._TA_C.v.(Ct) (SEQ ID No. 15).

Example 3

Producing an *E. coli* strain overexpressing the genes MSMEG_2956 from *Mycobacterium smegmatis* and *npt* from *Nocardia* sp., *ald* from *Bacillus subtilis* and Cv2025 from *Chromobacterium violaceum*

To generate an *E. coli* strain coexpressing the genes MSMEG_2956 from *Mycobacterium smegmatis* encoding a fatty acid reductase (YP_887275.1) and *npt* from *Nocardia* sp. encoding a phosphopantetheinyl transferase (ABI83656.1) which phosphopantetheinylates the fatty acid reductase, in combination with the genes *ald* from *Bacillus subtilis* encoding an alanine dehydrogenase (NP_391071.1) and Cv2025 from *Chromobacterium violaceum* encoding a transaminase (NP_901695.1), the strain *E. coli* W3110 was transformed with the plasmids pACYC{Placuv5}[carA_Ms-npt_Noc] (SEQ ID No. 10) and pJ281_alaDH_B.s._TA_C.v.(ct) (SEQ ID No. 15) by means of electroporation and plated out on LB agar plates containing chloramphenicol (50 µg/ml) and kanamycin (50 µg/ml). Transformants were checked as regards the presence of the correct plasmids by plasmid preparation and analytical restriction analysis.

The strain generated was referred to as *E. coli* W3110 pACYC{Placuv5}[carA_Ms-npt_Noc] / pJ281_alaDH_B.s._TA_C.v.(ct). The strain was used to investigate its capability for the production of dodecanediamine proceeding from dodecanedioic acid and dodecylamine proceeding from dodecanoic acid. The gene product CarA, a fatty acid reductase which is activated by the overexpressed phosphopantetheinyl transferase *npt*, converts the substrate

dodecanoic acid or dodecanedioic acid to the respective aldehyde or dialdehyde. The function of the gene product Cv_2505 is that of converting the (di)aldehyde terminally to the dodecylamine or dodecanediamine. The alanine amino donor required for the amination reaction is provided from pyruvate by the gene product *ald*.

5

Example 4

Production of dodecanediamine and dodecylamine by *E. coli* strains containing an expression vector for the genes MSMEG_2956 from *Mycobacterium smegmatis* and *npt* from *Nocardia* sp. in combination with an expression vector for the genes *ald* from *Bacillus subtilis* and Cv_2025 from *Chromobacterium violaceum*

The strain generated in example 3 was used to investigate its capability in relation to the production of dodecylamine and dodecanediamine. The biotransformation of dodecanoic acid and dodecanedioic acid to dodecylamine and dodecanediamine, respectively, was carried out in the 8-fold parallel fermentation system from DASGIP. The procedure for this was as follows:

For the fermentation, 1 L reactors were used. The pH probes were calibrated by means of a two-point calibration with measurement solutions of pH 4.0 and pH 7.0. The reactors were filled with 300 mL of drinking water and autoclaved for 20 min at 121°C in order to ensure sterility. Then, the pO₂ probes were polarized on the DASGIP system overnight (for at least 6 h). The next morning, the water was removed under the clean bench and replaced with 300 mL of high-cell-density medium containing 50 mg/L chloramphenicol and 50 mg/L kanamycin. Subsequently, the pO₂ probes were calibrated using a single-point calibration (stirrer: 400 rpm / aeration: 10 sL/h air) and the feed, correcting agent and induction agent paths were cleaned by means of clean-in-place. To this end, the hoses were flushed with 70% ethanol, then with 1 M NaOH, then with sterile demineralized water and finally filled with the particular media.

The *E. coli* strain producing dodecanediamine and dodecylamine was firstly cultured from the cryogenic culture in LB medium (25 mL in a 100 mL baffled flask) containing the aforementioned antibiotics overnight at 37°C and 200 rpm, for about 18 h. Then, 2 mL of the culture were inoculated into high-cell-density medium (15 g/L glucose (30 mL/L of a separately autoclaved 500 g/L stock solution containing 1% MgSO₄·7H₂O and 2.2% NH₄Cl), 1.76 g/L (NH₄)₂SO₄, 19.08 g/L K₂HPO₄, 12.5 g/L KH₂PO₄, 6.66 g/L yeast extract, 2.24 g/L trisodium citrate dihydrate, ammonium ferric citrate solution, 17 mL/L of a separately autoclaved 1% strength stock solution, trace element solution, 5 mL/L separately autoclaved stock solution (36.50 g/L HCl (37%), 1.91 g/L MnCl₂·4H₂O, 1.87 g/L ZnSO₄·7H₂O, 0.84 g/L

ethylenediaminetetraacetic acid dihydrate, 0.30 g/L H_3BO_3 , 0.25 g/L $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$, 4.70 g/L $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$, 17.80 g/L $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 0.15 g/L $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$) (25 mL in a 100 mL baffled flask) containing the aforementioned antibiotics and incubated at 37°C / 200 rpm for a further 5.5 h.

The reactors were inoculated at an optical density of 0.1 by an appropriate volume of the pre-culture being filled into a 5 mL syringe (under sterile conditions) and the reactors being inoculated by means of a needle across a septum covered with 70% ethanol.

The following standard program was used:

DO regulator		pH regulator	
Preset	0%	Preset	0 mL/h
P	0.1	P	5
Ti	300 s	Ti	200 s
Min	0%	Min	0 mL/h
Max	100%	Max	40 mL/h

10

N (rotation)	from	to	XO ₂ (gas mixture)	from	to	F (gas flow rate)	from	to
Growth and biotransformation	0%	30%	Growth and biotransformation	0%	100%	Growth and biotransformation	15%	80%
	400 rpm	1500 rpm		21 %	21%		6 sL/h	72 sL/h

Script	
Trigger activated	31% DO (1/60 h)
IPTG induction	2 h after feed start
Feed trigger	50% DO
Feed rate	3 [mL/h]

The experiment carried out can be divided into two phases: growth, during which the cells are to reach a certain optical density, and subsequent biotransformation, in which, after addition of the substrates dodecanoic acid, oleic acid and dodecanedioic acid, a conversion to dodecylamine, oleylamine and dodecanediamine, respectively, is to take place by enzymes formed during expression. The pH levels were unilaterally adjusted to pH 6.8 using ammonia (12.5%). During growth and biotransformation, the dissolved oxygen (DO) in the culture was adjusted at 30% by means of stirrer speed and aeration rate. The fermentation was carried out as a fed batch, with the feed start, 5 g/Lh glucose feed (500 g/L glucose containing 1% $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ and 2.2% NH_4Cl), being triggered via a DO peak. With the feed start, the temperature was also lowered

from previously 37°C to 30°C. The expression of the transaminase, alanine dehydrogenase, carboxylic acid reductase and phosphopantetheinyl transferase was induced 2 h after the feed start by the automated addition of 1 mM IPTG. Before the start of biotransformation, the optical density of the culture broths was determined.

5

The start of the biotransformation phase took place 1 h or 12 h after the feed start. To this end, 150 mL or 75 mL of a mixture of dodecanoic acid or dodecanedioic acid and oleic acid (technical-grade 90%) were added as a batch to the fermentation broth. To provide an amino group donor for the transaminase, 5 mL of a 3 M ammonium sulphate solution were added to the fermentation broth 30 minutes before the biotransformation start. For sampling, 2 mL of fermentation broth were removed from the tank and a portion thereof was diluted 1/20 in a and in a mixture of 80% acetonitrile, 20% water and 0.1% formic acid and extracted. Samples were taken from all reactors at 1.25 h, 2.75 h, 4.25 h, 18.25 h, and 21.75 h after the start of biotransformation. The conversion rates for oxygen (OTR = oxygen transfer rate) and carbon (CTR = carbon transfer rate) were determined during the fermentation via the waste-gas analyses on the DASGIP systems. The fermentation was ended 21.75 h after the start of biotransformation. The stirrer, the aeration system, the temperature control and pH control were turned off and the tanks were left to stand undisturbed for 5-10 minutes.

20 *HPLC-ESI/MS scan method*

The samples were qualitatively assessed by means of HPLC/MS coupling with high-resolution MS detection in the scan mode.

The following instruments were used here:

- Accela HPLC system (Thermo Scientific, Waltham, Massachusetts, USA) with autosampler, quaternary pump, PDA detector and column oven
- LTQ-FT mass spectrometer (Thermo Scientific, Waltham, Massachusetts, USA) with ESI source
- HPLC column: Kinetex C18, 100 x 2.1 mm, particle size: 2.6 µm, pore size 100 Å (Phenomenex; Aschaffenburg)

30

The samples were prepared by pipetting 1950 µl of solvent (80% (v/v) acetonitrile, 20% double-distilled H₂O (v/v), + 0.1% formic acid) and 50 µl of sample into a 2 ml reaction vessel. The mixture was vortexed for about 10 seconds and then centrifuged at about 13 000 rpm for 5 min. The clear supernatant was removed using a pipette.

The HPLC separation was carried out with the aforementioned HPLC column. The injection volume was 0.5 μ L, the column temperature 40°C, and the flow rate 0.3 mL/min. The mobile phase was composed of eluent A (0.02% strength (v/v) aqueous trifluoroacetic acid) and eluent B (acetonitrile with 0.015% (v/v) trifluoroacetic acid). The following gradient profile was used:

Time [min]	Eluent A [%]	Eluent B [%]
0	98	2
2	98	2
17	2	98
32	2	98

5

The ESI-MS analysis was carried out in the positive mode with the following parameters of the ESI source:

- ESI voltage: 4kV
- Capillary temperature 300°C
- Sheath gas flow 40
- Aux gas flow 5
- Sweep gas flow 3

10

The detection was carried out within a mass range of $m/z = 100$ to 1000. The mass spectrometry resolution was $R = 100\,000$.

15

The results are shown in the table below.

Substrate	Induction	MS intensity [-]		
		Dodecanediamine	Dodecylamine	Oleylamine
LA/oleic acid (150 ml)	1 mM IPTG (12 h)	n.d.	1,160,000	23,700
DDA/oleic acid (75 ml)	1 mM IPTG in H ₂ O/ethanol (12 h)	742,000	n.d.	18,000
DDA/oleic acid (150 ml)	1 mM IPTG (1 h)	30,700	n.d.	n.d.
DDA/oleic acid (150 ml)	1 mM IPTG (12 h)	23,500	n.d.	n.d.

20

Qualitative detection of monoamines and diamines in the fermentation broth of the strain *E.coli* W3110 pACYC{Placuv5}[carA_Ms-npt_Noc] / pJ281_alaDH_B.s_TA_C.v(ct) after a 21.75 h process time (n.d. = not detectable, LA = lauric acid, DDA = dodecanedioic acid).

Further data are illustrated in figure 1.

- 5 1,12-dodecanediamine and dodecylamine are quantitatively determined by means of HPLC/UV measurement, after derivatization by means of ortho-phthaldialdehyde. The methanolic supernatant was measured. The most important chromatographic parameters are summarized in the following table.

Column	Luna 5u C8, 100 Å, 150 x 4.60 mm (Phenomenex; Aschaffenburg)
HPLC system	Agilent 1200
Eluent A	2.5 mL of acetic acid (100%) to 1 L of double-distilled water, pH adjustment with sodium hydroxide solution to pH 6.0
Eluent B	methanol
Column temp.	40 °C
Flow rate	1 mL/min
Gradient	0.0-1 min: 30.0% B, 1.0-17.0 min: 90.0% B, 17-19.5 min: 90.0% B, 19.6-20.5 min: 30.0% B
Detector	DAD, 334 nm
Derivatization/ injection volume	Automatic derivatization by means of injector program, 1 µL of sample is reacted with 9 µL of derivatization reagent; composition of derivatization reagent: 10 g/L o-phthaldialdehyde dissolved in borate buffer (0.4 mol/L), with addition of mercaptoethanol (5 mL/L) and methanol (100 mL/L)
Calibration	External calibration, measurement range 50-1000 mg/L, 5-point calibration, calibration before and after the sample series, averaging via both calibration series, quadratic regression

- 10 The results are shown in the tables which follow.

Substrate	Induction	Dodecylamine [mg/L]	Dodecanediamine [mg/L]
DDA/oleic acid (75 ml)	1 mM IPTG in H ₂ O/ethanol (12 h)	n.d.	40.5

DDA/oleic acid (150 mL)	1 mM IPTG (1 h)	n.d.	3.1
DDA/oleic acid (150 ml)	1 mM IPTG (12 h)	n.d.	<1 [*]
LA/oleic acid (150 ml)	1 mM IPTG (12 h)	11.6	n.d.

Quantification of monoamines and diamines in the fermentation broth of the strain *E.coli* W3110 pACYC{Placuv5}[carA_Ms-npt_Noc] / pJ281_alaDH_B.s._TA_C.v.(ct) after a 21.75 h process time (n.d. = not detectable, ^{*} lower than the detection limit, DDA = dodecanedioic acid, LA = lauric acid).

- 5 It was shown that the strains are capable of producing, from dodecanoic acid, dodecanedioic acid and oleic acid, the respective amines dodecylamine, dodecanediamine and oleylamine.

Example 5

- 10 **Producing an expression vector for the expression of the gene α DOX encoding an α -dioxygenase from *Oryza sativa***

To produce a vector for the expression of α DOX (Os12g0448900, SEQ ID No. 16) from *Oryza sativa* encoding an α -dioxygenase (NP_001066718.1), the gene was codon-optimized for expression in *Escherichia coli*, synthesized and, at the same time, an upstream *NdeI* restriction site and a downstream *AvrII* restriction site were introduced. The synthesized DNA fragment was digested with the restriction endonucleases *NdeI* and *AvrII* and ligated into the correspondingly cut vector pACYC{Placuv5}[carA_Ms-npt_Noc] (SEQ ID No. 10) with removal of the genes *carA_Ms* and *npt_Noc*. The *lacuv5* promoter (SEQ ID No. 3) present in the vector was retained. The finished vector was referred to as pACYC{Placuv5}[DOX_Os(co_Ec)] (SEQ ID No. 17). The vector pACYC is an *E. coli* vector which mediates chloramphenicol resistance and also bears a p15A origin of replication and thus has a low copy number (10-15 copies per cell).

- 25 Example 6

Producing an *E. coli* strain having a deletion in the gene *bioH*, overexpressing the genes α DOX from *Oryza sativa*, *ald* from *Bacillus subtilis* and Cv2025 from *Chromobacterium violaceum*

- To generate an *E. coli* strain which coexpresses the gene α DOX from *Oryza sativa* encoding an α -dioxygenase (NP_001066718.1) in combination with the genes *ald* (SEQ ID No. 11) from

- Bacillus subtilis* encoding an alanine dehydrogenase (NP_391071.1) and Cv2025 (SEQ ID No. 12) from *Chromobacterium violaceum* encoding a transaminase (NP_901695.1), the strain *E. coli* W3110 Δ bioH (production: see EP12007663, example 1) was transformed with the plasmids pACYC{Placuv5}[DOX_Os(co_Ec)] (SEQ ID No. 17) and
- 5 pJ281_alaDH_B.s._TA_C.v.(ct) (SEQ ID No. 15) by means of electroporation and plated out on LB agar plates containing chloramphenicol (50 µg/ml) and kanamycin (50 µg/ml). Transformants were checked as regards the presence of the correct plasmids by plasmid preparation and analytical restriction analysis. The strain generated was referred to as *E. coli* Δ bioH pACYC{Placuv5}[DOX_Os(co_Ec)] / pJ281_alaDH_B.s._TA_C.v.(ct).
- 10 The strain was used to investigate its capability for the production of methyl aminoundecanoate proceeding from methyl dodecanedioate.

Example 7

- 15 **Production of methyl aminoundecanoate proceeding from methyl dodecanedioate by an *E. coli* strain containing an expression vector for the gene α DOX from *Oryza sativa* in combination with an expression vector for the genes *ald* from *Bacillus subtilis* and Cv_2025 from *Chromobacterium violaceum***

- The strain described in example 8 was used to investigate its capability in relation to the
- 20 production of methyl aminoundecanoate. The procedure for this was as follows:

- The strain under investigation was firstly spread out on an LB agar plate containing 50 µg/ml chloramphenicol and 50 µg/ml kanamycin and incubated overnight at 37°C. As control, the strain *E. coli* W3110 Δ bioH was additionally spread out on an LB agar plate not containing antibiotics. The strains were then cultured in Luria-Bertani broth, Miller (Merck, Darmstadt)
- 25 containing 50 µg/ml chloramphenicol and 50 µg/ml kanamycin (for the plasmid-bearing strain) as a 20 ml pre-culture from a single colony in each case. As main culture, 100 ml of LB broth containing 50 µg/ml chloramphenicol and 50 µg/ml kanamycin were initially charged into a 500 ml Erlenmeyer flask containing baffles and inoculated with 2 ml from the pre-culture. Culturing was firstly carried out at 37°C and 200 rpm in an incubator shaker. Upon attainment of an
- 30 optical density (600 nm) of 0.5 – 0.7, the gene expression was induced by addition of 1 mM IPTG. Further culturing was carried out overnight at 22°C and 200 rpm. The following day, the cultures were harvested by a 10-minute centrifugation at 4°C and 5525 x g. The supernatant was discarded and the cell pellet washed in 200 mM potassium phosphate buffer (pH 7.5). The cell pellet was lastly taken up in 200 mM potassium phosphate buffer containing 50 mM

ammonium chloride and 0.5% (w/v) glucose, and so an OD (600 nm) of 20 was attained. 12.5 mM methyl dodecanedioate (abcr, Karlsruhe) in ethanol were added to the cell suspension and gently shaken for 4 hours at 30°C and 300 rpm. During the incubation, samples were taken at the times 0 min, 60 min, 120 min, 180 min and 240 min and extracted in a mixture of 80%
5 acetonitrile, 20% water and 0.1% formic acid. The supernatant was analysed by means of HPLC/MS analysis. The results are shown in the table below.

Strain	Time [min]	Peak area Methyl aminoundecanoate
<i>E. coli</i> W3110 Δ bioH	0	n.d.
	120	n.d.
	180	n.d.
	240	n.d.
<i>E. coli</i> W3110 Δ bioH pACYC{Placuv5}[DOX] / pJ281_alaDH_B.s._TA_C.v.(ct)	0	n.d.
	120	57616
	180	371989
	240	1764605

Production of methyl aminoundecanoate with *E. coli* W3110 Δ bioH overexpressing α DOX from *Oryza sativa*, *ald* from *Bacillus subtilis* and Cv_2025 from *Chromobacterium violaceum*. Peak areas are specified (n.d. = not detectable).

5

It was possible to show that the strain *E. coli* W3110 Δ bioH pACYC{Placuv5}[DOX] / pJ281_alaDH_B.s._TA_C.v.(ct) is capable of forming methyl aminoundecanoate proceeding from methyl dodecanedioate.

10

Claims

1. Whole-cell catalyst which expresses a recombinant α -dioxygenase or the combination of a recombinant fatty acid reductase and of a phosphopantetheinyl transferase which phosphopantetheinylates the fatty acid reductase, and which additionally expresses a transaminase, wherein the phosphopantetheinyl transferase and/or transaminase is preferably recombinant.
2. Whole-cell catalyst according to Claim 1, wherein the whole-cell catalyst additionally expresses an amino acid dehydrogenase which is preferably recombinant.
3. Whole-cell catalyst according to either of Claims 1 and 2, wherein the whole-cell catalyst additionally expresses an alkane hydroxylase which is preferably recombinant.
4. Whole-cell catalyst according to any of Claims 1 to 3, wherein the whole-cell catalyst additionally expresses a polypeptide of the AlkL family, which polypeptide is preferably recombinant.
5. Whole-cell catalyst according to any of Claims 1 to 4, which additionally expresses an alcohol dehydrogenase which is preferably recombinant.
6. Whole-cell catalyst according to any of Claims 1 to 5, wherein the activity of at least one enzyme involved in the β -oxidation is reduced with respect to the wild type of the whole-cell catalyst.
7. Whole-cell catalyst according to any of Claims 1 to 6, wherein the activity of BioH or a variant thereof is reduced or elevated with respect to the wild type of the whole-cell catalyst.
8. Whole-cell catalyst according to any of Claims 1 to 7, wherein the activity of FadL or a variant thereof is elevated with respect to the wild type of the whole-cell catalyst.
9. Process for converting a carboxylic acid or dicarboxylic acid or a monoester thereof to an amine or diamine, comprising the steps of

a) providing a carboxylic acid or dicarboxylic acid or a monoester thereof, in the case of a dicarboxylic acid, preferably by contacting a carboxylic acid with an alkane hydroxylase and/or alcohol dehydrogenase,

5 b) contacting the carboxylic acid or dicarboxylic acid or the monoester thereof with a phosphopantetheinylated fatty acid reductase or an α -dioxxygenase to form an aldehyde product, and

c) contacting the aldehyde product from step a) with a transaminase.

10

10. Process according to Claim 9, wherein an amino acid dehydrogenase is present in step c).

11. Process according to any of Claims 9 to 10, wherein at least one enzyme from the group comprising phosphopantetheinylated fatty acid reductase, α -dioxxygenase, transaminase,
15 amino acid dehydrogenase and alkane hydroxylase, preferably all the enzymes used from said group, are provided in the form of a whole-cell catalyst according to any of Claims 1 to 8.

15

12. Process according to any of Claims 9 to 11, wherein the carboxylic acid or dicarboxylic acid
20 or the monoester thereof is a compound of the formula (I)

20



where R^1 is selected from the group comprising -H and $COOR^3$,

25

where R^2 and R^3 are each independently selected from the group comprising H, methyl, ethyl and propyl,

with the proviso that at least one of the radicals R^2 and R^3 is H,

30

where A is an unbranched, branched, linear, cyclic, substituted or unsubstituted hydrocarbon group having at least four carbons.

13. Process according to any of Claims 9 to 12, wherein A has the formula - (CH₂)_n -, where n is at least 4, preferably at least 10.

14. Use of the whole-cell catalyst according to any of Claims 1 to 8 or of the process according to any of Claims 8 to 12 for aminating a carboxylic acid or dicarboxylic acid or a monoester thereof.

15. Reaction mixture comprising the whole-cell catalyst according to any of Claims 1 to 8 in aqueous solution and also a carboxylic acid or dicarboxylic acid or a monoester thereof of the formula (I)



where R¹ is selected from the group comprising -H and COOR³,

where R² and R³ are each independently selected from the group comprising H, methyl, ethyl and propyl,

with the proviso that at least one of the radicals R² and R³ is H,

where A is an unbranched, branched, linear, cyclic, substituted or unsubstituted hydrocarbon group having at least four carbons, preferably the formula - (CH₂)_n -, where n is at least 4, particularly preferably at least 10.

1194101_1.txt
SEQUENCE LISTING

<110> Evonik Industries AG

<120> Producing amines and diamines from a carboxylic acid
or dicarboxylic acid or a monoester thereof

<130> 2012000206

<160> 17

<170> PatentIn version 3.5

<210> 1

<211> 3507

<212> DNA

<213> Mycobacterium smegmatis

<400> 1

atgacgatcg aaacgcgcga agaccgcttc aaccggcgca ttgaccactt gttcgaaacc	60
gacccgcagt tcgccgccgc ccgtcccgcg gaggcgatca gcgcggctgc cgccgatccg	120
gagttgcgcc ttcttgccgc ggtcaaacag attctggccg gctatgcgga ccgccctgcg	180
ctcggcaagc gcgccgtcga gttcgtcacc gacgaagaag gccgcaccac cgcaagctc	240
ctgccccgct tcgacaccat cacctaccgt cagctcgag gccggatcca ggccgtgacc	300
aatgcctggc acaaccatcc ggtgaatgcc ggtgaccgcg tggccatcct gggtttcacc	360
agtgtcgact acacgacgat cgacatcgcc ctgctcgaa tcggcgccgt gtccgtaccg	420
ctgcagacca gtgcgccggt ggcccaactg cagccgatcg tcgccgagac cgagcccaag	480
gtgatcgctg cgagcgtcga cttcctcgcc gacgcagtcg ctctcgtcga gtccggggcc	540
gcgccgtcgc gactggtggt gttcgactac agccacgagg tcgacgatca gcgtgaggcg	600
ttcgaggcgg ccaaggga gctcgcaggc accggcgctg tcgtcgagac gatcaccgac	660
gtactggacc gcgggcggtc actcgccgac gcaccgctct acgtgcccga cgagaccgac	720
ccgtgaccc ttctcatcta cacctccggc agcaccggca ctccaaggg cgcgatgtac	780
cccgagtcca agaccgccac gatgtggcag gccgggtcca agggccgggt ggacgagacc	840
ctcggcgatga tgccgtcaat caccctgaac ttcatgccca tgagtcacgt catggggcgc	900
ggcatcctgt gcagcacact cgccagcggc ggaaccgcgt acttcgccgc acgcagcgac	960
ctgtccacct tcctggagga cctcgccctc gtgcggccca cgcagctcaa cttcgttcct	1020
cgcatctggg acatgctgtt ccaggagtac cagagccgcc tcgacaaccg ccgcgccgag	1080
ggatccgagg accgagccga agccgcagtc ctgaagagg tccgcacca actgctcggc	1140
gggcgattcg tttcggccct gaccggatcg gctcccatct cggcgagat gaagagctgg	1200
gtcgaggacc tgctcgacat gcatctgctg gagggtctac gctccaccga ggccggcgcg	1260
gtgttcacat acgggcagat ccagcggccg ccggtcatcg actacaagct ggtcgacgtg	1320
cccgatctcg gctacttcgc caccgaccgg ccctaccgcg gcggcgaact tctggtcaag	1380
tccgagcaga tgttccccgg ctactacaag cgtccggaga tcaccgccga gatgttcgac	1440
gaggacgggt actaccgcac cggcgacatc gtcgccgagc tcggggccga ccatctcgaa	1500

1194101_1.txt

tacctcgacc gccgcaacaa cgtgctgaaa ctgtcgcagg gcgaattcgt cacggtctcc	1560
aagctggagg cgggtgttcgg cgacagcccc ctggtacgcc agatctacgt ctacggcaac	1620
agcgcgcggt cctatctgct ggcggtcgtg gtcccgcacc aagaggcact gtcacgttgg	1680
gacggtgacg aactcaagtc gcgcatcagc gactcactgc aggacgcggc acgagccgcc	1740
ggattgcagt cgtatgagat cccgcgtgac ttcctcgtcg agacaacacc tttcacgctg	1800
gagaacggcc tgctgaccgg tatccgcaag ctggcccggc cgaaactgaa ggcgcactac	1860
ggcgaacgcc tcgaacagct ctacaccgac ctggccgagg ggcaggccaa cgagttgcgc	1920
gagttgcgcc gcaacggagc cgaccggccc gtggtcgaga ccgtcagccg cgccgcggtc	1980
gcactgctcg gtgcctccgt cacggatctg cgggtccgatg cgacttcac cgatctgggt	2040
ggagattcgt tgtcggcctt gagcttctcg aacctgttgc acgagatctt cgatgtcgac	2100
gtgccggtcg gcgtcatcgt cagcccggcc accgacctgg caggcgtcgc ggcctacatc	2160
gagggcgaaac tgcgcggctc caagcgcccc acatacgct cggtgcacgg gcgcgacgcc	2220
accgaggtgc gcgcgcgtga tctcgccctg ggcaagttca tcgacgcaa gacctgtcc	2280
gccgcgccgg gtctgcgcg ttcgggcacc gagatccgca ccgtgctgct gaccggcgcc	2340
accgggttcc tgggccccta tctggcgctg gaatggctgg agcgcatgga cctggtggac	2400
ggcaaggtga tctgcctgggt gcgcgcccgc agcgacgacg agggccgggc gcgtctggac	2460
gccacgttcg acaccgggga cgcgacactg ctcgagcact accgcgcgct ggcagccgat	2520
cacctcgagg tgatcgccgg tgacaagggc gagggccgatc tgggtctcga ccacgacag	2580
tggcagcgac tggccgacac cgtcgatctg atcgtcgatc cggccgccct ggtcaatcac	2640
gtcctgccgt acagccagat gttcggaccc aatgcgctcg gcaccgccga actcatccgg	2700
atcgcgctga ccaccacgat caagccgtac gtgtacgtct cgacgatcgg tgtgggacag	2760
ggcatctccc ccgaggcgtt cgtcgaggac gccgacatcc gcgagatcag cgcgacgcgc	2820
cgggtcgacg actcgtacgc caacggctac ggcaacagca agtgggcccgg cgaggtcctg	2880
ctgcgggagg cgcacgactg gtgtggctcg ccggtctcgg tgttccgctg cgacatgatc	2940
ctggccgaca cgacctactc gggtcagctg aacctgccgg acatgttcac ccgcctgatg	3000
ctgagcctcg tggcgaccgg catcgcgccc ggttcgttct acgaactcga tgcggacggc	3060
aaccggcagc gcgcccacta cgacgggctg cccgtggagt tcatcgccga ggcgatctcc	3120
accatcggtc cgcaggtcac cgacggatc gagacgttcc acgtgatgaa cccgtacgac	3180
gacggcatcg gcctcgacga gtacgtggac tggctgatcg aggcgggcta ccccgtcac	3240
cgcgtcgacg actacgccac ctggctgagc cggttcgaaa ccgactgcg ggccctgccg	3300
gaacggcaac gtcaggcctc gctgctgccg ctgctgcaca actatcagca gccctcaccg	3360
cccgtgtgcg gtgccatggc acccaccgac cggttccgtg ccgcggtgca ggacgcgaag	3420
atcgggcccc acaaggacat tccgcacgtc acggccgacg tgatcgtcaa gtacatcagc	3480
aacctgcaga tgctcggatt gctgtaa	3507

<210> 2
 <211> 672
 <212> DNA
 <213> *Nocardia* sp.

<400> 2
 atgatacaga caattttgcc tgctggtgtc gagtcggctg agctgctgga gtatccggag 60
 gacctgaagg cgcataccggc ggaggagcat ctcatcgcga agtcggtgga gaagcggcgc 120
 cgggacttca tcggggccag gcattgtgcc cggctggcgc tggctgagct cggcgagccg 180
 ccggtggcga tcggcaaagg ggagcggggg gcgccgatct ggccgcgcgg cgtcgtcggc 240
 agcctcacc cttgcgacgg atatacggcc gcggcgggtg cgcacaagat gcgcttccgt 300
 tcgatacggc tcgataccga gccgcacgcg acgctgcccg aaggcgtgct ggattcggtc 360
 agcctgccc cggagcggga gtggttgaag accaccgatt ccgcactgca cctggaccgt 420
 ttactgttct gcgccaagga agccacctac aaggcgtggt ggccgctgac cgcgcgctgg 480
 ctggccttcg aggaagcgcga catcaccttc gagatcgaag acggctccgc cgattccggc 540
 aacggcacct ttcacagcga gctgctggtg ccgggacaga cgaatgacgg tgggacgccg 600
 ctgctttcgt tcgacggccg gtggctgata gccgacgggt tcatactcac cgcgatcgcg 660
 tacgcctgat aa 672

<210> 3
 <211> 153
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> promotor

<400> 3
 ggcagtgagc gcaacgcaat taatgtaagt tagctcactc attaggcacc ccaggcttga 60
 cactttatgc ttccggctcg tataatgtgt ggaattgtga gcggataaca ataacaattt 120
 cacacaggat ctaggaacca aggagagtgg cat 153

<210> 4
 <211> 34
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 4
 ttatgcgact cctgctggct atggtgggat ttcc 34

<210> 5
 <211> 29
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 5
 gatcgatcata tgccactctc cttggttcc 29

<210> 6
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 6
 tggcatatga cgatcgaaac gcgcg 25

<210> 7
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 7
 tcctttctctt acagcaatcc gagcatct 28

<210> 8
 <211> 32
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 8
 gctgtaagag aaggagttct atcatgatcg ag 32

<210> 9
 <211> 35
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 9
 gcagcctagg ttaatttatc aggcgtacgc gatcg 35

<210> 10
 <211> 8047
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Vector

<400> 10
 attaacctag gctgctgcca ccgctgagca ataactagca taacccttg gggcctctaa 60
 acgggtcttg aggggttttt tgctgaaacc tcaggcattt gagaagcaca cggtcacact 120
 gcttccggta gtcaataaac cggtaaacca gcaatagaca taagcggcta tttaacgacc 180

1194101_1.txt

ctgccctgaa ccgacgaccg ggtcgaattt gctttcgaat ttctgccatt catccgctta	240
ttatcactta ttcaggcgta gcaccaggcg ttttaagggca ccaataactg ccttaaaaaa	300
attacgcccc gccctgccac tcatcgcagt actgttgtaa ttcattaagc attctgccga	360
catggaagcc atcacagacg gcatgatgaa cctgaatcgc cagcggcatc agcaccttgt	420
cgccttgctg ataatatattg cccatagtga aaacgggggc gaagaagttg tccatattgg	480
ccacgtttta atcaaaactg gtgaaactca cccagggatt ggctgagacg aaaaacatat	540
tctcaataaa ccttttaggg aaataggcca ggttttcacc gtaacacgcc acatcttgcg	600
aatatatgtg tagaaactgc cggaaatcgt cgtggtattc actccagagc gatgaaaacg	660
tttcagtttg ctcatggaaa acggtgtaac aagggtgaac actatcccat atcaccagct	720
caccgtcttt cattgccata cggaaactcc gatgagcatt catcaggcgg gcaagaatgt	780
gaataaaggc cggataaaac ttgtgcttat ttttctttac ggtcttttaa aaggccgtaa	840
tatccagctg aacggtctgg ttataggtag attgagcaac tgactgaaat gcctcaaaat	900
gttcttttac atgccattgg gatatatcaa cgggtgtata tccagtgtt tttttctcca	960
ttttagcttc cttagctcct gaaaatctcg ataactcaa aaatacgcgc ggtagtgtac	1020
ttatttcatt atggtgaaag ttggaacctc ttacgtgccg atcaacgtct ctttttcgcc	1080
aaaagtggc ccagggtctc ccggtatcaa cagggaacac aggtatttatt tattctgcga	1140
agtgtcttc cgtcacaggc atttattcgg cgcaaagtgc gtcgggtgat gctgccaact	1200
tactgattta gtgtatgatg gtgtttttga ggtgtctccg tggcttctgt ttctatcagc	1260
tgccctcct gttcagctac tgacggggtg gtgcgtaacg gcaaaagcac cgccggacat	1320
cagcgttagc ggagtgtata ctggcttact atgttggcac tgatgagggg gtcagtgaag	1380
tgcttcatgt ggcaggagaa aaaaggctgc accggtgcgt cagcagaata tgtgatacag	1440
gatatatctc gcttctcgc tctagtactc gctacgctc gtcgttcgac tgcggcgagc	1500
ggaaatggc tacgaacggg gcggagattt cctggaagat gccaggaga tacttaacag	1560
ggaagtgaga gggccgccc aaagccgtt tccataggc tccgcccccc tgacaagcat	1620
cacgaaatct gacgtcaaa tcatgtgtg cgaaacccga caggactata aagataccag	1680
gcgtttcccc tggcggctcc ctctgtcgt ctctgttcc tgcctttcgg tttaccggtg	1740
tcattccgct gttatggccg cgtttgtctc attccacgcc tgacactcag ttccgggtag	1800
gcagtctgct ccaagctgga ctgtatgcac gaaccccccg ttcagtccga ccgctgcgcc	1860
ttatccggta actatcgtct tgagtccaac ccggaagac atgcaaaagc accactggca	1920
gcagccactg gtaattgatt tagaggagtt agtcttgaag tcatgcgccg gtttaaggcta	1980
aactgaaagg acaagttttg gtgactgcgc tcctccaagc cagttacctc ggttcaaaga	2040
gttggttagc cagagaacct tcgaaaaacc gccctgcaag gcggtttttt cgttttcaga	2100
gcaagagatt acgcgcagac caaacgatc tcaagaagat catcttatta atcagataaa	2160
atatttctag atttcagtgc aatttatctc ttcaaagtga gcacctgaag tcagcccat	2220

1194101_1.txt

acgatataag ttgtaattct catgttagtc atgccccgcg cccaccggaa ggagctgact	2280
gggttgaagg ctctcaaggg catcggtcga gatccccgtg cctaatagag gagctaactt	2340
acattaattg cgttgcgctc actgcccgtt ttccagtcgg gaaacctgtc gtgccagctg	2400
cattaatgaa tcggccaacg cgcggggaga ggcggtttgc gtattgggcg ccagggtggg	2460
ttttcttttc accagtgaga cgggcaacag ctgattgccc ttcaccgcct ggccctgaga	2520
gagttgcagc aagcgggtcca cgctgggttg ccccagcagg cgaaaatcct gtttgatggg	2580
ggttaacggc gggatataac atgagctgtc ttcggtatcg tcgtatcca ctaccgagat	2640
gtccgcacca acgcgcagcc cggactcggg aatggcgcgc attgcgcca gcgccatctg	2700
atcgttgga accagcatcg cagtgggaac gatgccctca ttcagcattt gcatggtttg	2760
ttgaaaaccg gacatggcac tccagtcgcc ttcccgttcc gctatcggct gaatttgatt	2820
gcgagtgaga tatttatgcc agccagccag acgcagacgc gccgagacag aacttaatgg	2880
gcccgtaac agcgcgattt gctggtgacc caatgcgacc agatgtcca cgcccagtcg	2940
cgtaccgtct tcatgggaga aaataatact gttgatgggt gtctggtcag agacatcaag	3000
aaataacgcc ggaacattag tgcaggcagc ttccacagca atggcatcct ggtcatccag	3060
cggatagtta atgatcagcc cactgacgcg ttgcgcgaga agattgtgca ccgccgcttt	3120
acaggcttcg acgccgcttc gttctaccat cgacaccacc acgctggcac ccagttgatc	3180
ggcgcgagat ttaatcgccg cgacaatttg cgacggcgcg tgcagggcca gactggagggt	3240
ggcaacgcc atcagcaacg actgtttgcc cgccagttgt tgtgccacgc ggttggaat	3300
gtaattcagc tccgccatcg ccgcttcac tttttccgc gttttcgag aaacgtggct	3360
ggcctggttc accacgcggg aaacggtctg ataagagaca ccggcatact ctgcgacatc	3420
gtataacggt actggtttca cattcaccac cctgaattga ctctcttccg ggcgctatca	3480
tgccataacc cgaaagggtt tgcgccattc gatggtgtcc gggatctcga cgctctccct	3540
tatgcgactc ctgctggcta tgggtgggatt tcccttgctg aaatgggaga tccgatcatg	3600
ttcgagctct tattcaata cactgctgtg ttggcggtaa gcgttctcga gcgcggccgc	3660
gcgatcgcac ctggtgttta aacggccggc ccctgcaggg gcagtgagcg caacgcaatt	3720
aatgtaagtt agctcactca ttaggcaccc caggcttgac actttatgct tccggctcgt	3780
ataatgtgtg gaattgtgag cggataacaa taacaatttc acacaggatc taggaaccaa	3840
ggagagtggc atatgacgat cgaaacgcgc gaagaccgct tcaaccggcg cattgaccac	3900
ttgttcgaaa ccgaccgca gttcgccgcc gcccgctccc acgaggcgat cagcgcggct	3960
gccgccgatc cggagttagc ctttctgcc gcggtcaaac agattctggc cggctatgag	4020
gaccgccctg cgctcggaac gcgcgccgtc gagttcgtca ccgacgaaga aggccgcacc	4080
accgcgaagc tcctgccccg cttcgacacc atcacctacc gtcagctcgc aggccggatc	4140
caggccgtga ccaatgcctg gcacaacat ccggtgaatg ccggtgaccg cgtggccatc	4200
ctgggtttca ccagtgtcga ctacacgacg atcgacatcg ccctgctcga actcggcgcc	4260

1194101_1.txt

gtgtccgtac	cgctgcagac	cagtgcgccg	gtggcccaac	tgcagccgat	cgtcgccgag	4320
accgagccca	aggtgatcgc	gtcgagcgtc	gacttcctcg	ccgacgcagt	cgctctcgtc	4380
gagtcggggc	ccgcgccgtc	gcgactggtg	gtgttcgact	acagccacga	ggtcgacgat	4440
cagcgtgagg	cgttcgaggc	ggccaagggc	aagctcgcag	gcaccggcgt	cgtcgtcgag	4500
acgatcaccg	acgtactgga	ccgcgggcgg	tactcgcgcg	acgcaccgct	ctacgtgccc	4560
gacgagaccg	acccgctgac	ccttctcatc	tacacctccg	gcagcaccgg	cactcccaag	4620
ggcgcgatgt	accccagagtc	caagaccgcc	acgatgtggc	aggccgggtc	caaggcccgg	4680
tgggacgaga	ccctcggcgt	gatgccgtca	atcacctga	acttcatgcc	catgagtcac	4740
gtcatggggc	gcggcatcct	gtgcagcaca	ctcgccagcg	gcggaaccgc	gtacttcgcc	4800
gcacgcagcg	acctgtccac	cttctggag	gacctgccc	tcgtgcggcc	cacgcagctc	4860
aacttcgttc	ctcgcatctg	ggacatgctg	ttccaggagt	accagagccg	cctcgacaac	4920
cgccgcgccg	agggatccga	ggaccgagcc	gaagccgcag	tcctcgaaga	ggtcgcgacc	4980
caactgctcg	gcgggcgatt	cgtttcggcc	ctgaccggat	cggctcccat	ctcggcggag	5040
atgaagagct	gggtcgagga	cctgctcgac	atgcatctgc	tggagggcta	cggctccacc	5100
gaggccggcg	cggtgttcat	cgacgggcag	atccagcgcc	cgcgggtcat	cgactacaag	5160
ctggtcgacg	tgcccgatct	cggctacttc	gccacggacc	ggccctaccc	gcgcggcgaa	5220
cttctgggtca	agtccgagca	gatgttcccc	ggctactaca	agcgtccgga	gatcaccgcc	5280
gagatgttcg	acgaggacgg	gtactaccgc	accggcgaca	tcgtcgccga	gctcggggcc	5340
gaccatctcg	aatacctcga	ccgccgcaac	aacgtgctga	aactgtcgca	gggcgaattc	5400
gtcacggtct	ccaagctgga	ggcgggtgtc	ggcgacagcc	ccctggtacg	ccagatctac	5460
gtctacggca	acagcgcgcg	gtcctatctg	ctggcggtcg	tgggtcccgac	cgaagaggca	5520
ctgtcacgtt	gggacggtga	cgaactcaag	tcgcgcatca	gcgactcact	gcaggacgcg	5580
gcacgagccg	ccggattgca	gtcgtatgag	atcccgcggtg	acttcctcgt	cgagacaaca	5640
cctttcacgc	tggagaacgg	cctgctgacc	ggtatccgca	agctggcccc	gccgaaactg	5700
aaggcgcaact	acggcgcaacg	cctcgaacag	ctctacaccg	acctggccga	ggggcaggcc	5760
aacgagttgc	gcgagttgcg	ccgcaacgga	gccgaccggc	ccgtgggtcga	gaccgtcagc	5820
cgcgccgcgg	tcgcactgct	cgggtgcctcc	gtcacggatc	tgcggtccga	tgcgcacttc	5880
accgatctgg	gtggagattc	gttgtcggcc	ttgagcttct	cgaacctggt	gcacgagatc	5940
ttcgatgtcg	acgtgccgggt	cggcgtcatc	gtcagcccgg	ccaccgacct	ggcaggcgtc	6000
gcggcctaca	tcgagggcga	actgcgcggc	tccaagcgcc	ccacatacgc	gtcgggtcac	6060
gggcgcgacg	ccaccgaggt	gcgcgcgcgt	gatctcgccc	tgggcaagtt	catcgacgcc	6120
aagaccctgt	ccgccgcgcc	gggtctgccc	cgttcgggca	ccgagatccg	caccgtgctg	6180
ctgaccggcg	ccaccggggt	cctggggccgc	tatctggcgc	tggaatggct	ggagcgcgatg	6240
gacctggtgg	acggcaagggt	gatctgcctg	gtgcgcgccc	gcagcgacga	cgaggcccgg	6300

1194101_1.txt

gcgcgtctgg	acgccacggt	cgacaccggg	gacgcgacac	tgctcgagca	ctaccgcgcg	6360
ctggcagccg	atcacctcga	ggtgatcgcc	ggtgacaagg	gcgaggccga	tctgggtctc	6420
gaccacgaca	cgtggcagcg	actggccgac	accgtcgatc	tgatcgtcga	tccggccgcc	6480
ctggtcaatc	acgtcctgcc	gtacagccag	atgttcggac	ccaatgcgct	cggcaccgcc	6540
gaactcatcc	ggatcgcgct	gaccaccacg	atcaagccgt	acgtgtacgt	ctcgacgatc	6600
ggtgtgggac	agggcatctc	ccccgaggcg	ttcgtcgagg	acgccgacat	ccgcgagatc	6660
agcgcgacgc	gccgggtcga	cgactcgtac	gccaacggct	acggcaacag	caagtgggcc	6720
ggcgagggtc	tgctgcggga	ggcgcacgac	tggtgtggtc	tgccggtctc	ggtgttccgc	6780
tgcgacatga	tcctggccga	cacgacctac	tcgggtcagc	tgaacctgcc	ggacatgttc	6840
acccgcctga	tgctgagcct	cgtggcgacc	ggcatcgcg	ccggttcggt	ctacgaactc	6900
gatgcggacg	gcaaccggca	gcgcgcccac	tacgacgggc	tgcccgtgga	gttcatcgcc	6960
gaggcgatct	ccaccatcgg	ctcgcaggtc	accgacggat	tcgagacgtt	ccacgtgatg	7020
aacccgtacg	acgacggcat	cggcctcgac	gagtacgtgg	actggctgat	cgaggccggc	7080
taccccgctg	accgcgtcga	cgactacgcc	acctggctga	gccggttcga	aaccgcactg	7140
cgggccctgc	cggaacggca	acgtcaggcc	tcgctgctgc	cgctgctgca	caactatcag	7200
cagccctcac	cgcccggtg	cggtgccatg	gcacccaccg	accggttcgg	tgccgcggtg	7260
caggacgcga	agatcgggcc	cgacaaggac	attccgcacg	tcacggccga	cgtgatcgtc	7320
aagtacatca	gcaacctgca	gatgctcgga	ttgctgtaag	agaaggagtt	ctatcatgat	7380
cgagacaatt	ttgcctgctg	gtgtcgagtc	ggctgagctg	ctggagtatc	cggaggacct	7440
gaaggcgcat	ccggcggagg	agcatctcat	cgcgaaagtc	gtggagaagc	ggcgccggga	7500
cttcatcggg	gccaggcatt	gtgcccggct	ggcgtggct	gagctcggcg	agccgccggg	7560
ggcgatcggc	aaaggggagc	gggtgctgcc	gatctggccg	cgcggcgtcg	tcggcagcct	7620
cacccattgc	gacggatata	gggccgcggc	ggtggcgcac	aagatgcgct	tccgttcgat	7680
cggcatcgat	gccgagccgc	acgcgacgct	gcccgaaggc	gtgctggatt	cggtcagcct	7740
gccgccggag	cgggagtggt	tgaagaccac	cgattccgca	ctgcacctgg	accgtttact	7800
gttctgcgcc	aaggaagcca	cctacaaggc	gtggtggccg	ctgaccgcgc	gctggctcgg	7860
cttcgaggaa	gcgcacatca	ccttcgagat	cgaagacggc	tccgccgatt	ccggcaacgg	7920
cacctttcac	agcgagctgc	tggtgccggg	acagacgaat	gacggtggga	cgccgctgct	7980
ttcgttcgac	ggccggtggc	tgatcgccga	cgggttcatc	ctcaccgcga	tcgcgtacgc	8040
ctgataa						8047

<210> 11
 <211> 1137
 <212> DNA
 <213> Bacillus subtilis

<400> 11
 atgatcatag ggggttcctaa agagataaaa aacaatgaaa accgtgtcgc attaacaccc 60

1194101_1.txt

gggggcggtt	ctcagctcat	ttcaaacggc	caccgggtgc	tggttgaaac	aggcgcgggc	120
cttggaagcg	gatttgaaaa	tgaagcctat	gagtcagcag	gagcggaaat	cattgctgat	180
ccgaagcagg	tctgggacgc	cgaaatggtc	atgaaagtaa	aagaaccgct	gccggaagaa	240
tatgtttatt	ttcgcaaagg	acttgtgctg	tttacgtacc	ttcatttagc	agctgagcct	300
gagcttgcac	aggccttgaa	ggataaagga	gtaactgcc	tcgcatatga	aacggtcagt	360
gaaggccgga	cattgcctct	tctgacgcca	atgtcagagg	ttgcgggcag	aatggcagcg	420
caaatcggcg	ctcaatttct	agaaaagcct	aaaggcggaa	aaggcattct	gcttgccggg	480
gtgcctggcg	tttcccgcgg	aaaagtaaca	attatcgagg	gaggcgttgt	cgggacaaac	540
gcggcgaaaa	tggctgtcgg	cctcggtgca	gatgtgacga	tcattgactt	aaacgcagac	600
cgcttgcgcc	agcttgatga	catcttcggc	catcagatta	aaacgttaat	ttctaaccg	660
gtcaatattg	ctgatgctgt	ggcgggaagc	gatctcctca	tttgcgcggt	attaattccg	720
ggtgctaaag	ctccgactct	tgtcactgag	gaaatggtaa	aacaaatgaa	acccggttca	780
gttattgttg	atgtagcgat	cgaccaaggc	ggcatcgctg	aaactgtcga	ccatatacaca	840
acacatgatc	agccaacata	tgaaaaacac	ggggttgctg	attatgctgt	agcgaacatg	900
ccaggcgagc	tccctcgtag	atcaacaatc	gccctgacta	acgttactgt	tccatacgcg	960
ctgcaaatcg	cgaacaaagg	ggcagtaaaa	gcgctcgag	acaatacggc	actgagagcg	1020
ggtttaaa	ccgcaaacgg	acacgtgacc	tatgaagctg	tagcaagaga	tctaggctat	1080
gagtatgttc	ctgccgagaa	agctttacag	gatgaatcat	ctgtggcggg	tgcttaa	1137

<210> 12
 <211> 1380
 <212> DNA
 <213> Chromobacterium violaceum

<400> 12						
atgcagaaac	agcgtaccac	ctctcagtgg	cgtgaactcg	atgcggcgca	tcattctccat	60
ccgtttaccg	ataccgcgag	cctcaatcag	gcgggtgctg	gtgtgatgac	ccgtggcgaa	120
ggcgtgtatc	tctgggatag	cgaaggcaac	aaaattattg	atggcatggc	gggcctctgg	180
tgcgatgaac	tgggctatgg	ccgtaaagat	tttgcggaag	cggcgcgtcg	tcagatggaa	240
gaactcccgt	tttataaac	cttctttaaa	accacccatc	cggcggtggt	ggaactcagc	300
agcctcctcg	ccgaagttac	cccggcaggt	tttgatcggt	tgttttatac	caacagcggc	360
agcgaagc	tgataccat	gattcgtatg	gtgcgtcggt	attgggatgt	gcagggcaaa	420
ccggaaaaaa	aaaccctcat	tggccgttgg	aacggctatc	acggcagcac	cattggcggg	480
gcgagcctcg	gcggcatgaa	atatatgcat	gaacagggcg	atctcccgat	tccgggcatg	540
gcgcatattg	aacagccgtg	gtggtataaa	catggcaaag	atatgacccc	ggatgaattt	600
ggcgtgggtg	cggcgcggtg	gctcgaagaa	aaaattctcg	aaatcggcgc	ggataaagtg	660
gcggcgtttg	tgggcgaacc	gattcagggg	gcgggcgggt	tgattgttcc	gccggcaacc	720

1194101_1.txt

tattggccgg aaattgaacg tatttgccgc aaatatgatg tgctcctcgt tgcggatgaa	780
gtgatttgcg gctttggccg taccggcgaa tggtttgcc atcagcattt tggctttcag	840
ccggacctct ttaccgcggc gaaaggcctc agcagcggct atctcccgat tggcgcggtg	900
tttgtgggca aacgtgttgc ggaaggctctc attgcgggcg gtgattttaa ccatggcttt	960
acctatagcg gccatccggt gtgtgcggcg gtggcgcatg cgaatgttgc ggcgctccgt	1020
gatgaaggca ttgtgcagcg tgtgaaagat gatattggcc cgtatatgca gaaacgttgg	1080
cgtgaaacct ttagccgttt tgaacatgtg gatgatgtgc gtggcggtgg catggtgcag	1140
gcgtttaccc tcgtgaaaaa caaagcgaaa cgtgaactct ttccggattt tggcgaaatt	1200
ggcaccctct gcccgatat ttttttcgc aacaacctca ttatgcgtgc gtgcggcgat	1260
cacatttgtt ctgcaccgcc gctcgttatg acccgtcgg aagtggatga aatgctcgcc	1320
gtggcggaac gttgcctcga agaatttgaa cagaccctca aagcgcgtag cctcgccata	1380

<210> 13
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 13	
atgatcatag gggttcctaa agag	24

<210> 14
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 14	
ttaagcacc gccacagatg	20

<210> 15
 <211> 6866
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Vector

<400> 15	
atgatcatag gggttcctaa agagataaaa aacaatgaaa accgtgtcgc attaacaccc	60
gggggcgttt ctcagctcat ttcaaaccgc caccgggtgc tggttgaaac aggcgcgggc	120
cttgaagcg gatttgaaaa tgaagcctat gagtcagcag gagcggaat cattgctgat	180
ccgaagcagg tctgggacgc cgaaatggtc atgaaagtaa aagaaccgct gccggaagaa	240
tatgtttatt ttgcgaaagg acttggtgctg ttacgtacc ttcathtagc agctgagcct	300
gagcttgac aggccttgaa ggataaagga gtaactgcc tcgcatatga aacggtcagt	360

1194101_1.txt

gaaggccgga cattgcctct tctgacgcca atgtcagagg ttgcgggcag aatggcagcg	420
caaatcggcg ctcaattctt agaaaagcct aaaggcggaa aaggcattct gcttgccggg	480
gtgcctggcg tttcccgcgg aaaagtaaca attatcggag gaggcgttgt cgggacaaac	540
gcggcgaaaa tggctgtcgg cctcgggtga gatgtgacga tcattgactt aaacgcagac	600
cgcttgcgcc agcttgatga catcttcggc catcagatta aaacgttaat ttctaaccg	660
gtcaatattg ctgatgtgtt ggcggaagcg gatctcctca tttgcgcggt attaattccg	720
ggtgctaaag ctccgactct tgtcactgag gaaatggtaa aacaaatgaa acccggttca	780
gttattgttg atgtagcgat cgaccaaggc ggcacgtcgc aaactgtcga ccatatcaca	840
acacatgatc agccaacata tgaaaaacac ggggttgtgc attatgctgt agcgaacatg	900
ccaggcgcag tccctcgtac atcaacaatc gccctgacta acgttactgt tccatacgcg	960
ctgcaaatac cgaacaaagg ggcagtaaaa gcgctcgcag acaatacggc actgagagcg	1020
ggtttaaaca ccgcaaagcg acacgtgacc tatgaagctg tagcaagaga tctaggctat	1080
gagtatgttc ctgccgagaa agctttacag gatgaatcat ctgtggcggg tgcttaatta	1140
aggagatata atatgcagaa acagcgtacc acctctcagt ggcgtgaact cgatgcggcg	1200
catcatctcc atccgtttac cgataccgcg agcctcaatc aggcgggtgc gcgtgtgatg	1260
acccgtggcg aaggcgtgta tctctgggat agcgaaggca acaaaattat tgatggcatg	1320
gcgggcctct ggtgcgtgaa cgtgggctat ggccgtaaa attttgcgga agcggcgcgt	1380
cgtcagatgg aagaactccc gttttataac accttcttta aaaccacca tccggcgggtg	1440
gtggaactca gcagcctcct cgccgaagtt accccggcag gttttgatcg tgtgttttat	1500
accaacagcg gcagcgaaag cgtggatacc atgattcgta tgggtgcgtcg ttattgggat	1560
gtgcagggca aaccggaaaa aaaaaccctc attggccgtt ggaacggcta tcacggcagc	1620
accattggcg gtgcgagcct cggcggcatg aaatatatgc atgaacaggg cgatctcccg	1680
attccgggca tggcgcatat tgaacagccg tgggtggtata aacatggcaa agatatgacc	1740
ccggatgaat ttggcgtggt tgcggcgcgt tggctcgaag aaaaaattct cgaaatcggc	1800
gcggataaag tggcggcggt tgtgggcgaa ccgattcagg gtgcgggcgg tgtgattgtt	1860
ccgccggcaa cctattggcc ggaaattgaa cgtatttgcc gcaaatatga tgtgctcctc	1920
gttgcggatg aagtgatatt cggccttggc cgtaccggcg aatggtttgg ccatcagcat	1980
tttggttttc agccggacct ctttaccgcg gcgaaaggcc tcagcagcgg ctatctcccg	2040
attggcgcgg tgtttgtggg caaacgtgtt gcggaaggct tcattgcggg cggtgatttt	2100
aaccatggct ttacctatag cggccatccg gtgtgtgcgg cgggtggcgca tgcgaatgtt	2160
gcggcgctcc gtgatgaagg cattgtgcag cgtgtgaaag atgatattgg cccgtatatg	2220
cagaaacgtt ggcgtgaaac ctttagccgt tttgaacatg tggatgatgt gcgtggcgtg	2280
ggcatggtgc aggcgtttac cctcgtgaaa aacaaagcga aacgtgaact ctttccggat	2340
tttggcgaaa ttggcacctt ctgccgcgat attttttttc gcaacaacct cattatgcgt	2400

1194101_1.txt

gcgtgcggcg atcacattgt gtctgcaccg ccgctcgtta tgacccgtgc ggaagtggat	2460
gaaatgctcg ccgtggcgga acgttgccct gaagaatttg aacagaccct caaagcgcgt	2520
ggcctcgcct aataatctag atcaacaact ctctggcg accatcgtcg gctacagcct	2580
cgggaattgc tgcaagtcga cggatcgccg gaattaattc tcatgtttga cagcttatca	2640
ctgatcagtg aattaatggc gatgacgcat cctcacgata atatccgggt aggcgcaatc	2700
actttcgtct ctactccgtt acaaagcgag gctgggtatt tcccggcctt tttgggccgg	2760
ccggatcccc ccacttcaga agttcctata cactagagaa taggaacttc actatagagt	2820
cgaataaggg cgacaccccc taattagccc gggcgaaagg ccagtcctt cgactgagcc	2880
tttcgtttta tttgatgcct ggcagttccc tactctcgca tggggagtcc ccacactacc	2940
atcggcgcta cggcgtttca ctctgagtt cggcatgggg tcaggtggga ccaccgcgt	3000
actgccgcca ggcaaacaag ggggtgtatg agccatattc aggtataaat gggctcgca	3060
taatgttcag aattgggtta ttggttgtaa cactgacccc tatttgttta tttttctaaa	3120
tacattcaaa tatgtatccg ctcatgagac aataaccctg ataaatgctt caataatatt	3180
gaaaaaggaa gaatatgagc catattcaac gggaaacgtc gaggccgcga ttaaattcca	3240
acatggatgc tgatttatat gggataaat gggctcgca taatgtcggg caatcaggtg	3300
cgacaatcta tcgcttgat gggaaagccc atgcgccaga gttgtttctg aaacatggca	3360
aaggtagcgt tgccaatgat gttacagatg agatggtcag actaaactgg ctgacggaat	3420
ttatgccact tccgaccatc aagcatttta tccgtactcc tgatgatgca tggttactca	3480
ccactgcgat ccccgaaaa acagcgttcc aggtattaga agaatatcct gattcaggtg	3540
aaaatattgt tgatgcgctg gcagtgctc tgcgccggt gactcgatt cctgtttgta	3600
attgtccttt taacagcgat cgcgtatttc gcctcgctca ggcgcaatca cgaatgaata	3660
acggtttggt tgatgcgagt gattttgatg acgagcgtaa tggctggcct gttgaacaag	3720
tctggaaaga aatgcataaa cttttgccat tctcaccgga ttcagtcgtc actcatggtg	3780
atttctcact tgataacctt atttttgacg aggggaaatt aatagggtgt attgatgttg	3840
gacgagtcgg aatcgcagac cgataaccagg atcttgccat cctatggaac tgcctcgggtg	3900
agttttctcc ttcattacag aaacggcttt ttcaaaaata tggattgat aatcctgata	3960
tgaataaatt gcagtttcat ttgatgctcg atgagtttt ctaaaagcgg cgcgccatcg	4020
aatggcgcaa aacctttcgc ggtatggcat gatagcgccc ggaagagagt caattcaggg	4080
tggatgaatat gaaaccagta acgttatacg atgtcgcaga gtatgccgggt gtctcttatc	4140
agaccgtttc ccgctgggtg aaccaggcca gccacgtttc tgcgaaaacg cgggaaaaag	4200
tggaagcggc gatggcggag ctgaattaca ttcccaaccg cgtggcaca caactggcgg	4260
gcaaacagtc gttgctgatt ggcgttgcca cctccagtct ggccctgcac gcgccgtcgc	4320
aaattgtcgc ggcgattaaa tctcgcgccg atcaactggg tgccagcgtg gtggtgtcga	4380
tggtagaacg aagcggcgtc gaagcctgta aagcggcggg gcacaatctt ctgcgcgaac	4440

1194101_1.txt

gcgtcagtgg gctgatcatt aactatccgc tggatgacca ggatgccatt gctgtggaag	4500
ctgcctgcac taatgttccg gcgttatttc ttgatgtctc tgaccagaca cccatcaaca	4560
gtattatttt ctcccatgag gacggtacgc gactgggcgt ggagcatctg gtcgcattgg	4620
gtcaccagca aatcgcgctg ttagcgggcc cattaagttc tgtctcggcg cgtctgcgtc	4680
tggctggctg gcataaatat ctactcgcga atcaaattca gccgatagcg gaacgggaag	4740
gcgactggag tgccatgtcc ggttttcaac aaaccatgca aatgctgaat gagggcatcg	4800
ttcccactgc gatgctgggt gccaacgac agatggcgct gggcgcaatg cgcgccatta	4860
ccgagtccgg gctgcgctt ggtgcggata tctcgtagt gggatacgac gataccgaag	4920
atagctcatg ttatatcccg ccgttaacca ccatcaaaca ggattttcgc ctgctggggc	4980
aaaccagcgt ggaccgcttg ctgcaactct ctcagggcca ggcggtgaag ggcaatcagc	5040
tgttgccagt ctactgggtg aaaagaaaaa ccaccctggc gcccaatacg caaaccgcct	5100
ctccccgcgc gttggccgat tcattaatgc agctggcacg acagggttcc cgactggaaa	5160
gcgggcagtg actcatgacc aaaatccctt aacgtgagtt acgcgcgcgt cgttccactg	5220
agcgtcagac cccgtagaaa agatcaaagg atcttcttga gatccttttt ttctgcgcgt	5280
aatctgctgc ttgcaaacaa aaaaaccacc gctaccagcg gtggtttgtt tgccggatca	5340
agagctacca actctttttc cgaaggtaac tggcttcagc agagcgcaga taccaaatac	5400
tgttcttcta gtgtagccgt agttagccca ccacttcaag aactctgtag caccgcctac	5460
atacctcgct ctgctaattc tgttaccagt ggctgctgcc agtggcgata agtcgtgtct	5520
taccgggttg gactcaagac gatagttacc ggataaggcg cagcggtcgg gctgaacggg	5580
gggttcgtgc acacagccca gcttggagcg aacgacctac accgaactga gatacctaca	5640
gcgtgagcta tgagaaagcg ccacgcttcc cgaagggaga aaggcggaca ggtatccggt	5700
aagcggcagg gtcggaacag gagagcgac gagggagctt ccagggggaa acgcctggta	5760
tctttatagt cctgtcgggt ttcgccacct ctgacttgag cgtcgatttt tgtgatgtc	5820
gtcagggggg cggagcctat ggaaaaacgc cagcaacgcg gcctttttac ggttcctggc	5880
cttttgctgg ccttttgctc acatgttctt tcctgcgtta tcccctgatt ctgtggataa	5940
ccgtattacc gcctttgagt gagctgatac cgctcgccgc agccgaacga ccgagcgag	6000
cgagtcagt agcgaggaag cggaaggcga gagtagggaa ctgccaggca tcaaactaag	6060
cagaaggccc ctgacggatg gcctttttgc gtttctacaa actctttctg tgttgtaaaa	6120
cgacggccag tcttaagctc gggccccctg ggcggttctg ataacgagta atcgttaatc	6180
cgaaataaac gtaaaaaccc gcttcggcgg gtttttttat ggggggagtt tagggaaaga	6240
gcatttgtca gaatatttaa gggcgctgt cactttgctt gatatatgag aattatttaa	6300
ccttataaat gagaaaaaag caacgcactt taaataagat acgttgcttt ttcgattgat	6360
gaacacctat aattaaacta ttcattctatt atttatgatt ttttgtatat acaatatttc	6420
tagtttgttt aagagaatta agaaaaataa tctcgaaaat aataaaggga aaatcagttt	6480

1194101_1.txt

ttgatatcaa aattatacat gtcaacgata atacaaaata taatacaaac tataagatgt	6540
tatcagtatt tattatgcat ttagaataaa ttttgtgtcg cccttattcg actcactata	6600
gaagttccta ttctctagta agtataggaa cttcacttca ttttggatcc ggccggcctg	6660
cagccccgca gggcctgtct cggtcgatca ttcagccccg ctcatagata tgcgggcagt	6720
gagcgcaacg caattaatgt aagttagctc actcattagg caccacaggc ttgacacttt	6780
atgcttcccg ctcgtataat gtgtggaatt gtgagcggat aacaataaca atttcacaca	6840
ggatctagga accaaggaga gtggca	6866

<210> 16
 <211> 1857
 <212> DNA
 <213> Oryza sativa

<400> 16	
atgggttctg gtctgttcaa gccgcgtgtt caccggatc tgcgtgacgt tttctctaaa	60
atgtctttct tcgacaaaat cggtttctctg ttcattccacg cgttcgacaa acgtaacctg	120
tggcacaaag ttccggttcc gatcgggtctg ctgtacctga acaccgctcg taccctgctg	180
gaaaaataca atctgtctggc cgttggtcgt tcttctcacg gtgcgctgtt cgacccaaaa	240
gaattcctgt accgtaccga agatggtaaa tacaatgacc cgcacaacgc ggaagccggc	300
tctcaaaaca ctttctttgg tcgcaacatg gagccggttg accagcagga cgaactgatg	360
tctccggacc cgttcgttgt tgcgaccaa ctgttggcgc gtcgtgaata caaagacacc	420
ggcaaacagt tcaacatcct ggcggcagcg tggatccagt tcatggttca cgattggatg	480
gaccacatgg aggacaccgg tcaaattggt atcaccgcgc cgaaagaagt tgcgaacgaa	540
tgcccgctga aatctttcaa attccaccgg acgaaagaac tgccgaccaa ctctgacggt	600
atcaaaatcg gtactacaa catccgtacc gcgtggtggg acggttctgc ggtttacggt	660
aacaatgaag aacgtgcgga aaaactgctg acctacgttg acggtaaact ggttatcggg	720
gatgacggtc tgctgtctga caaagaaaac ggtgttgccg tgtctggtga catccgcaac	780
tcttggggcg gcgtttctat cctgcaggct ctgttcgtta aagaacacaa cgcggtttgc	840
gacgcgatca aggaagaaca cccgaacctg tctgacgaag aactgtaccg ttacgcgaaa	900
ctggttacct ctgcggttat cgcgaaagt caccaccatcg actggaccgt tgaactgctg	960
aagacaaaaa ccatgcgtgc ggcgatgcgt gcgaactggt acggcctgct gggtaaaaaa	1020
atcaagaca cttttggcca catcggtggt ccgatcctgg gtggtctggt tggctctgaa	1080
aaaccaaaca accacggtgt tccgtactct ctgactgaag aattcacctc tgtgtatcgt	1140
atgcactctc tgatcccgtc taccctgaaa ctgcgtgacc cgaccggtca gccggacgcg	1200
aataactctc cgccgtgcct ggaagacatc gacatcgggt agatgatcgg tctgaaagggt	1260
gaggaacagc tgtctaaaat tggcttcgaa aaacaggcgc tgtctatggg ttaccaggcg	1320
tgtggtgcgc tggaaactgt gaactacccg tctttcttcc gtaacctgat cccacagaac	1380
ctggacggta ccaatcggtc tgaccgtatc gacctggcgg cgctggaagt ttatcgtgac	1440

1194101_1.txt

cgtgaacggt	ctgttccg	ttacaacgaa	ttccgtcgtc	gtctgttcct	gatcccgatc	1500
aaatcttggg	aagacctgac	ctctgacaaa	gacgcgattg	aaaccatccg	tgcgatctac	1560
ggtgacgacg	ttgaaaaact	ggacctgctg	gttggtctga	tggcggaaaa	gaaaatcaaa	1620
ggcttcgca	tctctgaaac	cgcggtcaac	atcttcatcc	tgatggcttc	tcgtcgtctg	1680
gaagcggacc	gtttcttcac	ctccaacttc	aacgaagaga	cgtaacacaa	aaaaggatatg	1740
cagtgggtta	aaaccaccga	aggtctgcgc	gacgttatca	accgtcacta	tccggaaatc	1800
accgcgaaat	ggatgaaatc	ttcttctg	ttctctgttt	gggacgcgga	ctactag	1857

<210> 17
 <211> 5704
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> vector

<400> 17	
ctaggctgct	gccaccgctg agcaataact agcataaccc cttggggcct ctaaaccgggt 60
cttgaggggt	tttttgctga aacctcaggc atttgagaag cacacgggtca cactgcttcc 120
ggtagtcaat	aaaccggtaa accagcaata gacataagcg gctatttaac gaccctgccc 180
tgaaccgacg	accgggtcga atttgctttc gaatttctgc cattcatccg cttattatca 240
cttattcagg	cgtagcacca ggcgtttaag ggcaccaata actgccttaa aaaaattacg 300
ccccgccctg	ccactcatcg cagtactgtt gtaattcatt aagcattctg ccgacatgga 360
agccatcaca	gacggcatga tgaacctgaa tcgccagcgg catcagcacc ttgtcgcctt 420
gcgtataata	tttgcccata gtgaaaacgg gggcgaagaa gttgtccata ttggccacgt 480
ttaaataaaa	actggtgaaa ctacccagg gattggctga gacgaaaaac atatttctaa 540
taaacccttt	agggaaatag gccaggtttt caccgtaaca cgccacatct tgcgaaatata 600
tgtgtagaaa	ctgccgaaa tcgtcgtggt attcactcca gagcgatgaa aacgtttcag 660
tttgctcatg	gaaaacggtg taacaagggt gaacactatc ccatatcacc agctcaccgt 720
ctttcattgc	catacggaac tccggatgag cattcatcag gcgggcaaga atgtgaataa 780
aggccggata	aaacttggtg ttatttttct ttacggtcct taaaaaggcc gtaatatcca 840
gctgaacggt	ctggttatag gtacattgag caactgactg aaatgcctca aaatgttctt 900
tacgatgcca	ttgggatata tcaacggtgg tatatccagt gatTTTTTtccatttttag 960
cttccttagc	tcctgaaaat ctcgataact caaaaaatac gcccggtagt gatcttattt 1020
cattatgggtg	aaagtgggaa cctcttacgt gccgatcaac gtctcatttt cgccaaaagt 1080
tggcccaggg	cttcccggta tcaacaggga caccaggatt tatttattct gcgaagtgat 1140
cttcggtcac	aggtatttat tcggcgcaaa gtgcgtcggg tgatgctgcc aacttactga 1200
tttagtgtat	gatggtgttt ttgaggtgct ccagtggctt ctgtttctat cagctgtccc 1260
tcctgttcag	ctactgacgg ggtggtgcgt aacggcaaaa gcaccgccgg acatcagcgc 1320

1194101_1.txt

tagcggagtg	tatactggct	tactatgttg	gcactgatga	gggtgtcagt	gaagtgcctc	1380
atgtggcagg	agaaaaaagg	ctgcaccggt	gcgtcagcag	aatatgtgat	acaggatata	1440
ttccgcttcc	tcgctcactg	actcgctacg	ctcggtcgtt	cgactgcggc	gagcggaaat	1500
ggcttacgaa	cggggcggag	atttcctgga	agatgccagg	aagatactta	acaggggaagt	1560
gagagggccg	cggcaaagcc	gtttttccat	aggctccgcc	cccctgacaa	gcatacacgaa	1620
atctgacgct	caaatcagtg	gtggcgaaac	ccgacaggac	tataaagata	ccaggcgttt	1680
cccctggcgg	ctccctcgtg	cgctctcctg	ttcctgcctt	tcggtttacc	gggtgctattc	1740
cgctgttatg	gccgcgtttg	tctcattcca	cgcctgacac	tcagttccgg	gtaggcagtt	1800
cgctccaagc	tggactgtat	gcacgaaccc	cccgttcagt	ccgaccgctg	cgccttatcc	1860
ggtaactatc	gtcttgagtc	caaccgggaa	agacatgcaa	aagcaccact	ggcagcagcc	1920
actggtaatt	gatttagagg	agttagtctt	gaagtcatgc	gccggttaag	gctaaactga	1980
aaggacaagt	tttggtgact	gcgctcctcc	aagccagtta	cctcggttca	aagagttggt	2040
agctcagaga	accttcgaaa	aaccgccctg	caaggcggtt	ttttcgtttt	cagagcaaga	2100
gattacgcgc	agacaaaaac	gatctcaaga	agatcatctt	attaatcaga	taaaatattt	2160
ctagatttca	gtgcaattta	tctcttcaaa	tgtagcacct	gaagtcagcc	ccatacgata	2220
taagttgtaa	ttctcatggt	agtcatgccc	cgcgccacc	ggaaggagct	gactgggttg	2280
aaggctctca	agggcatcgg	tcgagatccc	gggtgcctaat	gagtgcgcta	acttacatta	2340
attgcgttgc	gtcactgcc	cgctttccag	tcgggaaacc	tgctgtgcca	gctgcattaa	2400
tgaatcggcc	aacgcgcggg	gagaggcggg	ttgcgtattg	ggcgccaggg	tggtttttct	2460
tttcaccagt	gagacgggca	acagctgatt	gcccttcacc	gcctggccct	gagagagttg	2520
cagcaagcgg	tccacgctgg	tttgccccag	caggcgaaaa	tcctgtttga	tggtgggttaa	2580
cggcgggata	taacatgagc	tgtcttcggt	atcgtcgtat	cccactaccg	agatgtccgc	2640
accaacgcgc	agcccggact	cggtaatggc	gcgcattgcg	cccagcgcca	tctgatcgtt	2700
ggcaaccagc	atcgcagtg	gaacgatgcc	ctcattcagc	atttgcatgg	tttgttgaaa	2760
accggacatg	gcactccagt	cgccttccc	ttccgctatc	ggctgaattt	gattgagcgt	2820
gagatattta	tgccagccag	ccagacgcag	acgcgccgag	acagaactta	atggggccgc	2880
taacagcgcg	atttgctggt	gacccaatgc	gaccagatgc	tccacgcca	gtcgcgtacc	2940
gtcttcatgg	gagaaaataa	tactgttgat	gggtgtctgg	tcagagacat	caagaaataa	3000
cgccggaaca	ttagtgcagg	cagcttcac	agcaatggca	tcctgggtcat	ccagcggata	3060
gttaatgatc	agccactga	cgcgttgccg	gagaagattg	tgcaccgccg	ctttacaggc	3120
ttcgacgccg	cttcgttcta	ccatcgacac	caccacgctg	gcaccagtt	gatcggcgcg	3180
agatttaatc	gccgcgacaa	tttgcgacgg	cgcgtgcagg	gccagactgg	aggtggcaac	3240
gccaatcagc	aacgactgtt	tgcccggcag	ttgttggtcc	acgcggttgg	gaatgtaatt	3300
cagctccgcc	atcgccgctt	ccactttttc	ccgcgttttc	gcagaaacgt	ggctggcctg	3360

1194101_1.txt

gttcaccacg	cgaggaaacgg	tctgataaga	gacaccggca	tactctgcga	catcgataaa	3420
cggtactggg	ttcacattca	ccaccctgaa	ttgactctct	tccgggcgct	atcatgccat	3480
accgcgaaag	gttttgcgcc	attcgatggg	gtccggggtc	tcgacgctct	cccttatgcg	3540
actcctgctg	gctatgggtg	gatttccctt	gctgaaatgg	gagatccgat	catgttcgag	3600
ctcttattca	aatacactgc	tgtgttggtg	gtaagcggtc	tcgagcgctg	ccgctgctgc	3660
gcacctgggtg	tttaaacggc	cgccccctgc	aggggcagtg	agcgcaacgc	aattaatgta	3720
agttagctca	ctcattaggc	accccaggct	tgacacttta	tgcttccggc	tcgtataatg	3780
tgtggaattg	tgagcggata	acaataacaa	tttcacacag	gatctaggaa	ccaaggagag	3840
tggcatatgg	gttctgggtc	gttcaagccg	cgtgttcacc	cggatctgct	tgacgttttc	3900
tctaaaatgt	ctttcttcga	caaaatcggt	ttcctgttca	tccacgcgtt	cgacaaacgt	3960
aacctgtggc	acaaagtctc	ggttccgctc	gggtctgctg	acctgaacac	ccgtcgtacc	4020
ctgctggaag	aatacaatct	gctggccggt	gggtcttctt	ctcacgggtc	gctgttcgac	4080
ccaaaagaat	tctgtaccg	taccgaagat	ggtaaataca	atgaccgcga	caacgcggaa	4140
gccggctctc	aaaacacctt	ctttggctgc	aacatggagc	cgggttgacca	gcaggacgaa	4200
ctgatgtctc	cggaccggtt	cgttgttgct	accaaactgc	tggcgctgct	tgaatacaaa	4260
gacaccggca	aacagttcaa	catcctggcg	gcagcgtgga	tccagttcat	ggttcacgat	4320
tggatggacc	acatggagga	caccgggtca	attgggtatc	ccgcgccgaa	agaagtgtcg	4380
aacgaatgcc	cgctgaaatc	tttcaaattc	caccgcagca	aagaactgcc	gaccaactct	4440
gacgggtatc	aaatcgggtc	ctacaacatc	cgtaccgcgt	gggtgggacg	ttctgcgggt	4500
tacggtaaca	atgaagaacg	tgcggaaaaa	ctgcgtacct	acgttgacgg	taaactgggt	4560
atcgggtgat	acggtctgct	gctgcacaaa	gaaaacgggt	ttgcgctgtc	tggtgacatc	4620
cgcaactctt	ggcgggcggt	ttctatcctg	cagggtctgt	tcgttaaaga	acacaacgcg	4680
gtttgcgacg	cgatcaagga	agaacacccg	aacctgtctg	acgaagaact	gtaccgttac	4740
gcgaaactgg	ttacctctgc	ggttatcgcg	aaagttcaca	ccatcgactg	gaccgttgaa	4800
ctgctgaaga	caaaaacatc	gcgtgcggcg	atgcgtgcga	actggtacgg	cctgctgggt	4860
aaaaaaatca	aagacacctt	tgccacatc	gggtgtccga	tcctgggtgg	tctggttggt	4920
ctgaaaaaac	caaacaacca	cggtgttccg	tactctctga	ctgaagaatt	cacctctgtg	4980
tatcgtatgc	actctctgat	cccgtctacc	ctgaaactgc	gtgaccgcac	cggtcagccg	5040
gacgcgaata	actctccgcc	gtgcctggaa	gacatcgaca	tcggtgagat	gatcgggtctg	5100
aaagggtgag	aacagctgtc	taaaattggc	ttcgaaaaa	aggcgctgtc	tatgggttac	5160
caggcgtgtg	gtgcgctgga	actgtggaac	taccgcctt	tcttccgtaa	cctgatccca	5220
cagaacctgg	acggtaccaa	tcgttctgac	cgtatcgacc	tggcggtcgt	ggaagtttat	5280
cgtgaccgtg	aacgttctgt	tccgcgttac	aacgaattcc	gtcgtcgtct	gttcctgatc	5340
ccgatcaa	cttgggaaga	cctgacctct	gacaaagacg	cgattgaaac	catccgtgct	5400

1194101_1.txt

atctacggtg acgacgttga aaaactggac ctgctggttg gtctgatggc ggaaaagaaa	5460
atcaaaggct tcgcatctc tgaaaccgcg ttcaacatct tcatcctgat ggcttctcgt	5520
cgtctggaag cggaccgttt cttcacctcc aacttcaacg aagagacgta caccaaaaaa	5580
ggtatgcagt gggttaaaac caccgaaggt ctgcgcgacg ttatcaaccg tcactatccg	5640
gaaatcaccg cgaaatggat gaaatcttct tctgcgttct ctgtttggga cgcggactac	5700
tagc	5704